US20150190532A1 - Smooth muscle specific inhibition for anti-restenotic therapy - Google Patents
Smooth muscle specific inhibition for anti-restenotic therapy Download PDFInfo
- Publication number
- US20150190532A1 US20150190532A1 US14/390,988 US201314390988A US2015190532A1 US 20150190532 A1 US20150190532 A1 US 20150190532A1 US 201314390988 A US201314390988 A US 201314390988A US 2015190532 A1 US2015190532 A1 US 2015190532A1
- Authority
- US
- United States
- Prior art keywords
- gene
- nucleic acid
- vector
- target sequences
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 230000005764 inhibitory process Effects 0.000 title description 6
- 230000002769 anti-restenotic effect Effects 0.000 title description 2
- 210000002460 smooth muscle Anatomy 0.000 title 1
- 239000013598 vector Substances 0.000 claims abstract description 396
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 314
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 239
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 158
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 158
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 158
- 238000000034 method Methods 0.000 claims abstract description 99
- 230000014509 gene expression Effects 0.000 claims abstract description 54
- 108020005345 3' Untranslated Regions Proteins 0.000 claims abstract description 40
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 183
- 239000002679 microRNA Substances 0.000 claims description 180
- 210000002889 endothelial cell Anatomy 0.000 claims description 53
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 51
- 239000013603 viral vector Substances 0.000 claims description 45
- 108091028066 Mir-126 Proteins 0.000 claims description 42
- 101150115162 p27 gene Proteins 0.000 claims description 33
- 208000029078 coronary artery disease Diseases 0.000 claims description 30
- 238000010348 incorporation Methods 0.000 abstract description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 67
- 102000004169 proteins and genes Human genes 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 63
- 108090000765 processed proteins & peptides Proteins 0.000 description 60
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 229920001184 polypeptide Polymers 0.000 description 54
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 52
- 102400001093 PAK-2p27 Human genes 0.000 description 46
- 239000000203 mixture Substances 0.000 description 42
- 239000002773 nucleotide Substances 0.000 description 39
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 37
- 108091070501 miRNA Proteins 0.000 description 36
- 230000000295 complement effect Effects 0.000 description 33
- -1 miR-130a Proteins 0.000 description 31
- 241000701161 unidentified adenovirus Species 0.000 description 27
- 241000702421 Dependoparvovirus Species 0.000 description 23
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 22
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 108091028049 Mir-221 microRNA Proteins 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 208000037803 restenosis Diseases 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- 238000001556 precipitation Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 241000714474 Rous sarcoma virus Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 230000001177 retroviral effect Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 11
- 101001135385 Homo sapiens Prostacyclin synthase Proteins 0.000 description 11
- 241000714177 Murine leukemia virus Species 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 10
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 10
- 241000713826 Avian leukosis virus Species 0.000 description 10
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 10
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 10
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 10
- 101000835893 Homo sapiens Mothers against decapentaplegic homolog 4 Proteins 0.000 description 10
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 10
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 10
- 241001135569 Human adenovirus 5 Species 0.000 description 10
- 108091033773 MiR-155 Proteins 0.000 description 10
- 108091027766 Mir-143 Proteins 0.000 description 10
- 108091028684 Mir-145 Proteins 0.000 description 10
- 241000713869 Moloney murine leukemia virus Species 0.000 description 10
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 10
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 10
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 10
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 10
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 10
- 108700032504 Smad2 Proteins 0.000 description 10
- 101150102611 Smad2 gene Proteins 0.000 description 10
- 241000713896 Spleen necrosis virus Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 108091063986 let-7f stem-loop Proteins 0.000 description 10
- 108091057645 miR-15 stem-loop Proteins 0.000 description 10
- 108091027943 miR-16 stem-loop Proteins 0.000 description 10
- 108091091751 miR-17 stem-loop Proteins 0.000 description 10
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 10
- 108091041042 miR-18 stem-loop Proteins 0.000 description 10
- 108091062221 miR-18a stem-loop Proteins 0.000 description 10
- 108091050874 miR-19a stem-loop Proteins 0.000 description 10
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 10
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 10
- 108091037787 miR-19b stem-loop Proteins 0.000 description 10
- 108091049679 miR-20a stem-loop Proteins 0.000 description 10
- 108091039792 miR-20b stem-loop Proteins 0.000 description 10
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 description 10
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 description 10
- 108091062762 miR-21 stem-loop Proteins 0.000 description 10
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 10
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 10
- 108091048308 miR-210 stem-loop Proteins 0.000 description 10
- 108091061917 miR-221 stem-loop Proteins 0.000 description 10
- 108091063489 miR-221-1 stem-loop Proteins 0.000 description 10
- 108091055391 miR-221-2 stem-loop Proteins 0.000 description 10
- 108091031076 miR-221-3 stem-loop Proteins 0.000 description 10
- 108091080321 miR-222 stem-loop Proteins 0.000 description 10
- 108091070404 miR-27b stem-loop Proteins 0.000 description 10
- 108091027983 miR-378-1 stem-loop Proteins 0.000 description 10
- 108091089716 miR-378-2 stem-loop Proteins 0.000 description 10
- 108091034121 miR-92a stem-loop Proteins 0.000 description 10
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 9
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 9
- 238000013146 percutaneous coronary intervention Methods 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 239000003154 D dimer Substances 0.000 description 8
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 8
- 241000713666 Lentivirus Species 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 102100033075 Prostacyclin synthase Human genes 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000001715 carotid artery Anatomy 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 108010052295 fibrin fragment D Proteins 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 101000851526 Homo sapiens Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000701109 Human adenovirus 2 Species 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000000520 microinjection Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229960002930 sirolimus Drugs 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 5
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 241001135574 Human adenovirus 12 Species 0.000 description 5
- 241000701096 Human adenovirus 7 Species 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 241001414828 Aonidiella aurantii Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000011977 dual antiplatelet therapy Methods 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000008692 neointimal formation Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 235000008729 phenylalanine Nutrition 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 201000005665 thrombophilia Diseases 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 235000014393 valine Nutrition 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 206010003162 Arterial injury Diseases 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 3
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 3
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 3
- 102100029727 Enteropeptidase Human genes 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 3
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000034827 Neointima Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000003372 endocrine gland Anatomy 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000003499 exocrine gland Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 102000053745 human ENTPD1 Human genes 0.000 description 3
- 102000051047 human PTGIS Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 235000014705 isoleucine Nutrition 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003593 megakaryocyte Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000003151 transfection method Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 238000010152 Bonferroni least significant difference Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101150027101 CDKN1B gene Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000034906 Medical device complication Diseases 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000255985 Trichoplusia Species 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003253 miRNA assay Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000944361 Homo sapiens Cyclin-dependent kinase inhibitor 1B Proteins 0.000 description 1
- 108091069085 Homo sapiens miR-126 stem-loop Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000015846 Prostacyclin synthases Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 229940027030 altoprev Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940088033 calan Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940088024 isoptin Drugs 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229940092923 livalo Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940089504 lopressor Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 108091088639 miR-16a stem-loop Proteins 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000011675 multiple endocrine neoplasia type 4 Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940124643 non-selective drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108010064377 prostacyclin synthetase Proteins 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000023276 regulation of development, heterochronic Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940072252 zestril Drugs 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- cardiovascular diseases represent a significant medical problem in the USA and throughout the world, despite remarkable advances over the past few decades. From the 1990's to early 2000's, restenosis after balloon angioplasty and/or stent implantation occurred with an incidence of approximately 50% and 25%, respectively, leading to a significant limitation in its effectiveness.
- CAD coronary artery disease
- PCI Percutaneous coronary intervention
- VSMC vascular smooth muscle cells
- the advent of drug eluting stents, capable of delivering an inhibitor of cell proliferation in situ has decreased, but not eliminated, the occurrence of restenosis.
- the drugs that elute from the stent not only inhibit VSMC, but also EC proliferation and migration, increasing the risk of late thrombosis.
- therapies that would provide VSMC selective anti-proliferative activity without affecting EC.
- the present invention provides for the incorporation of target sequences for a microRNA into the 3′-UTR of a gene, such as, but not limited to, a tumor suppressor gene, that is present in an expression vector.
- a gene such as, but not limited to, a tumor suppressor gene
- the expression vector is used to specifically over-express the gene in one cell type that either does not express the microRNA, or has very low expression levels of the microRNA, while inhibiting the expression of the gene in another cell type that has higher expression levels of the microRNA.
- the present invention provides a nucleic acid vector comprising a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is the p27 gene.
- the microRNA is miR-126.
- the one or more target sequences comprise SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA.
- the target sequences for a microRNA are identical.
- the target sequences for a microRNA comprise SEQ ID NO:2.
- the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the vector is delivered to a cell of interest.
- the cell of interest is an endothelial cell.
- the invention provides an expression system comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is the p27 gene.
- the microRNA is miR-126.
- the one or more target sequences comprise SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA.
- the target sequences for a microRNA are identical.
- the target sequences for a microRNA comprise SEQ ID NO:2.
- the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- the invention provides a cell comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is the p27 gene.
- the microRNA is miR-126.
- the one or more target sequences comprise SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA.
- the target sequences for a microRNA are identical.
- the target sequences for a microRNA comprise SEQ ID NO:2.
- the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector. In one embodiment, the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell.
- the invention provides a pharmaceutical composition comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is the p27 gene.
- the microRNA is miR-126.
- the one or more target sequences comprise SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA.
- the target sequences for a microRNA are identical.
- the target sequences for a microRNA comprise SEQ ID NO:2.
- the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- the invention provides a method of treating or preventing a cardiovascular disease in a subject in need thereof, the method comprising administering a nucleic acid vector to the subject, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is the p27 gene.
- the microRNA is miR-126.
- the one or more target sequences comprise SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA.
- the target sequences for a microRNA are identical.
- the target sequences for a microRNA comprise SEQ ID NO:2.
- the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- the nucleic acid vector is delivered into a cell of the subject.
- the cell expresses the microRNA.
- the gene of interest is not expressed in the cell.
- the cell is an endothelial cell.
- the cell is a vascular smooth muscle cell.
- the cardiovascular disease is coronary artery disease.
- FIGS. 1A-D Schematic representation of p27-expressing viruses.
- FIG. 1A Control CMV virus (CMV)
- FIG. 1B p27 expressing adenovirus under the control of CMV promoter (p27).
- FIG. 1C p27 expressing adenovirus under the control of CMV promoter, containing four target sequences for mir-126 in their 3′UTR (p27-126TS).
- FIG. 1D Representative immunoblots for the indicated proteins from VSMC or HUVEC infected with adenovirus described in A-C at 20 pfu/cell or 50 pfu/cell respectively for 48 hr.
- FIGS. 2A-J Ad-p27-126TS preserves EC function in vitro.
- FIG. 2A Real Time qRT-PCR analysis of miR-126 ( FIGS. 2B-C ) Representative immunoblot of three independent experiments quantified by densitometry.
- FIG. 2D Proliferation assays of VSMC and EC infected with the indicated Ad. Migration assays of VSMC ( FIGS. 2E , F) and EC ( FIGS. 2G , H) infected with the indicated Ad; representative pictures at the indicated time points are shown.
- FIGS. 2I , J Network formation assay in EC. Orange scale bar indicates 100 ⁇ m (magnification 4 ⁇ ). All data shown are means ⁇ s.e.m.
- FIGS. 3A-E Effects of Ad-p27-126TS in an in vivo model of arterial injury.
- FIG. 3A Representative sections of rat carotid arteries immunostained for smooth muscle cell actin ( ⁇ SMA) and for the specific EC marker VE-Cadherin (VE-Cad). Nuclei were counterstained with DAPI. No positive staining was observed in the negative control sections. Orange scale bars: 100 ⁇ m (magnification 60 ⁇ , inlays show high magnification images), arrowheads indicate EC beyond the inner autofluorescent elastic laminae.
- FIG. 3B Neointima/media ratios and ( FIG. 3C ) endothelial coverage were calculated from 5 rats/group.
- FIG. 3C Neointima/media ratios and ( FIG. 3C ) endothelial coverage were calculated from 5 rats/group.
- FIGS. 4A-C Schematic representation of the used adenoviruses (Ad).
- a pAdTrack-CMV vector that contains a green fluorescence protein (GFP) under the control of a separate CMV promoter was used to generate three adenoviruses: FIG. 4A .
- the Ad-GFP contains only the sequence for GFP.
- FIG. 4B The Ad-p27 contains the sequences for GFP and p27.
- FIG. 4C The Ad-p27-126TS contains GFP and p27 that have four target sequences for miR-126 in its 3′UTR.
- FIGS. 5A-B Histological assessment of rat carotid arteries 2 weeks after injury and adenoviral infection.
- FIG. 5A To overcome the autofluorescence issues typical of the vascular sections, the efficiency of the Ad infection was evaluated by using a primary antibody against GFP, revealed by a Cy3-conjugated secondary antibody. Representative digital images are shown. Orange scale bar represents 100 ⁇ m (magnification 60 ⁇ ).
- FIG. 5B Representative sections stained with hematoxilyn/eosin (magnification 10 ⁇ , inlays show the whole arterial section in a 5 ⁇ magnification; orange scale bar represents 500 ⁇ m).
- p27 refers to the cyclin-dependent kinase inhibitor also known as p27 Kip1 , which is a member of the kinase inhibitor protein (KIP) family.
- KIP kinase inhibitor protein
- p27 is a protein encoded by the CDKN1B gene.
- the nucleic acid sequences of the gene encoding p27 including, but not limited to, the nucleic acid sequence of the open reading frame of the gene, is known in the art.
- the nucleic acid sequences of the gene encoding human p27 including, but not limited to, the nucleic acid sequence of the open reading frame of the human gene, is known in the art.
- the amino acid sequences of the p27 polypeptide and protein including, but not limited to, the amino acid sequences of the human p27 polypeptide and proteins, are known in the art.
- the GeneBank accession number of the nucleic acid sequence of human p27 is NM — 004064.
- the GeneBank accession number of the amino acid sequence of human p27 is NP — 004055.
- p27 is also known as KIP1; MEN4; CDKN4, MEN1B and P27KIP1.
- miR-126 refers to microRNA 126.
- the nucleic acid sequence of miR-126 is known in the art.
- the nucleic acid sequences of human miR-126 is known in the art.
- the GeneBank accession number of the nucleic acid sequence of human miR-126 is M10000471.
- VEC Human Umbilical Venous Endothelial Cells.
- EC Endothelial Cells
- VSMC Vascular Smooth Muscle Cells
- SMC smooth muscle cells
- Cardiovascular disease accounts for nearly one third of deaths globally, and Coronary Artery Disease (CAD) remains the number one cause of death in the United States (Heron M, Hoyert D L, Murphy S L, Xu J, Kochanek K D, Tejada-Vera B: Deaths: final data for 2006 . Natl Vital Stat Rep 57(14), 1-134 (2009)).
- CAD Coronary Artery Disease
- DES Drug-Eluting Stent
- BES bare-metal stents
- the anti-restenotic action of the drug lies at least in part, on its ability to up-regulate levels of p27, a widely expressed protein that inhibits cyclin-dependent kinases (cdks) complexes in G1 and S phases (Marx S O, Totary-Jain H, Marks A R: Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Intenr 4(1), 104-111 (2011).
- Newer stents and coronary devices are currently undergoing pre-clinical and clinical trials including DES with biodegradable polymers, polymer free DES, new coated stents, completely biodegradable stents, bifurcation stents and drug-eluting balloons.
- these new approaches continue to utilize non-selective antiproliferative drugs that inhibit both vascular smooth muscle cells (VSMC) and vascular endothelial cell (EC) proliferation, adversely affecting critical endothelial cell functions such as maintaining vascular tone, providing a permeable barrier, modulating adhesion, inflammation and thrombosis. Therefore, it is of paramount importance to develop therapeutic strategies that can selectively inhibit VSMC and other infiltrated cells without affecting EC functions.
- the present invention addresses this need.
- the present invention provides for the incorporation of target sequences for a microRNA into the 3′-UTR of a gene, such as, but not limited to, a tumor suppressor gene, that is present in an expression vector.
- a gene such as, but not limited to, a tumor suppressor gene
- the expression vector is used to specifically over-express the gene in one cell type that either does not express the microRNA, or has very low expression levels of the microRNA, while inhibiting the expression of the gene in another cell type that has higher expression levels of the microRNA.
- the present invention provides for the incorporation of target sequences for the VEC-specific miRNA, miR-126, into the 3′-UTR of p27 in a p27-expressing vector, to specifically over-express p27 in vascular smooth muscle cells (VSMC), without affecting endothelial cells (EC) that express mir-126 at higher levels than VSMC.
- VSMC vascular smooth muscle cells
- EC endothelial cells
- This strategy will result in the specific inhibition of VSMC proliferation, migration and neointimal formation, without affecting endothelial cells, because p27-expressing vectors will be targeted for degradation in endothelial cells.
- the invention can be used, for example, in conjunction with BMS implantation to provide the benefits of a DES without the concern of DES post-operative complications.
- the invention can be used, for example, for the inhibition of VSMC proliferation in altherosclerosis and arterial injury, as well as vascular access failure in hemodialysis patients.
- nucleic acid species are capable of modifying gene expression. These include antisense RNA, siRNA, microRNA, RNA and DNA aptamers, and decoy RNAs. Each of these nucleic acid species can inhibit target nucleic acid activity, including gene expression.
- MicroRNAs are a class of short (18-25 nt) non-coding RNAs (ncRNAs) that exist in a variety of organisms, including mammals, and are conserved in evolution. miRNAs are processed from hairpin precursors of 70 nt (pre-miRNA) which are derived from primary transcripts (pri-miRNA) through sequential cleavage by the RNAse III enzymes drosha and dicer. miRNAs can be encoded in intergenic regions, hosted within introns of pre-mRNAs or within ncRNA genes. Many miRNAs also tend to be clustered and transcribed as polycistrons and often have similar spatial temporal expression patterns. miRNAs have been found to have roles in a variety of biological processes including developmental timing, differentiation, apoptosis, cell proliferation, organ development, and metabolism.
- miRNA genes have been identified in the human genome.
- 2 miRNA genes miR15a and miR16a have been localized to a homozygously deleted region on chromosome 13 that is correlated with chronic lymphocytic leukemia (Calin et al. (2002), Proc. Natl. Acad. Sci. USA 99:15524-29).
- miRNA genes have been localized to a homozygously deleted region on chromosome 13 that is correlated with chronic lymphocytic leukemia (Calin et al. (2002), Proc. Natl. Acad. Sci. USA 99:15524-29).
- the distribution of miRNA genes throughout the genome, and the relationship of the miRNA genes to diverse chromosomal features has not been systematically studied.
- a further review of miRNAs is provided in U.S. Pat. No. 7,232,806, U.S. Patent Application Publication No.
- MicroRNAs can inhibit target nucleic acid activity, including gene expression.
- miRNAs can function via base paring with complementary nucleic acid sequences within mRNA molecules. The pairing of miRNAs with complementary mRNA molecules usually results in gene silencing via translational repression or target degradation. Animal miRNAs can exhibit only partial complementarity to their mRNA targets. A seed region of about 6-8 nucleotides in length at the 5′ end of an miRNA is thought to be an important determinant of target specificity. A given miRNA can have multiple different mRNA targets and a given target can be targeted by multiple miRNAs. For additional information on miRNAs, see also Ishida el al., 2013, miRNA-Based Therapeutic Strategies, Curr Anesthesiol Rep., 1(1):63-70, which is incorporated herein by reference in its entirety.
- the present invention provides a nucleic acid vector comprising a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical.
- the nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises a second gene of interest.
- the second gene of interest is a human gene.
- the second gene of interest is a non-human gene.
- the second gene of interest is p53.
- the second gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the second gene of interest is an antithrombotic gene.
- the second gene of interest is an anti-inflammatory gene.
- the second gene of interest is ENTPD1, TFPI or PTGIS.
- the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the vector comprises one target sequence.
- the vector comprises two target sequences.
- the vector comprises three target sequences.
- the vector comprises four target sequences.
- the vector comprises five target sequences.
- the vector comprises six target sequences.
- the vector comprises seven target sequences.
- the vector comprises eight target sequences.
- the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the viral vector is a lentiviral vector.
- the vector is a retroviral vector.
- adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12).
- the vector is an adeno-associated vector.
- adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2).
- lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2.
- retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV).
- oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- MMV Murine Leukemia Virus
- SNV Spleen Necrosis Virus
- RSV Rous sarcoma virus
- AMV Avian Leukosis Virus
- the vector is delivered to a cell of interest.
- Delivery can be conducted by any method known to one of skill in the art, including, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- the cell of interest is an endothelial cell.
- the cell of interest is a vascular smooth muscle cell.
- the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like.
- the cell may be a stem cell or a differentiated cell.
- Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- the cell of interest is a cancer cell.
- the cancer can be, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- the invention provides an expression system comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical.
- the nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises a second gene of interest.
- the second gene of interest is a human gene.
- the second gene of interest is a non-human gene.
- the second gene of interest is p53.
- the second gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the second gene of interest is an antithrombotic gene.
- the second gene of interest is an anti-inflammatory gene.
- the second gene of interest is ENTPD1, TFPI or PTGIS.
- the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the vector comprises one target sequence.
- the vector comprises two target sequences.
- the vector comprises three target sequences.
- the vector comprises four target sequences.
- the vector comprises five target sequences.
- the vector comprises six target sequences.
- the vector comprises seven target sequences.
- the vector comprises eight target sequences.
- the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the viral vector is a lentiviral vector.
- the vector is a retroviral vector.
- adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12).
- the vector is an adeno-associated vector.
- adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2).
- lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2.
- retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV).
- oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- MMV Murine Leukemia Virus
- SNV Spleen Necrosis Virus
- RSV Rous sarcoma virus
- AMV Avian Leukosis Virus
- the invention provides a cell comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical.
- the nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises a second gene of interest.
- the second gene of interest is a human gene.
- the second gene of interest is a non-human gene.
- the second gene of interest is p53.
- the second gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the second gene of interest is an antithrombotic gene.
- the second gene of interest is an anti-inflammatory gene.
- the second gene of interest is ENTPD1, TFPI or PTGIS.
- the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the vector comprises one target sequence.
- the vector comprises two target sequences.
- the vector comprises three target sequences.
- the vector comprises four target sequences.
- the vector comprises five target sequences.
- the vector comprises six target sequences.
- the vector comprises seven target sequences.
- the vector comprises eight target sequences.
- the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the viral vector is a lentiviral vector.
- the vector is a retroviral vector.
- adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12).
- the vector is an adeno-associated vector.
- adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2).
- lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2.
- retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV).
- oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- MMV Murine Leukemia Virus
- SNV Spleen Necrosis Virus
- RSV Rous sarcoma virus
- AMV Avian Leukosis Virus
- the cell expresses the microRNA. In another embodiment, the cell does not express the microRNA.
- the gene of interest is not expressed in the cell. In another embodiment, the gene of interest is expressed in the cell. In one embodiment, the second gene of interest is not expressed in the cell. In another embodiment, the second gene of interest is expressed in the cell.
- the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell. In further embodiments, the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell.
- Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- the cell is a cancer cell.
- the cancer is, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- the nucleic acid vector is delivered into the cell by any method known to one of skill in the art, such as, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- the present invention utilizes conventional molecular biology, microbiology, and recombinant DNA techniques available to one of ordinary skill in the art. Such techniques are well known to the skilled worker and are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, “Molecular Cloning: A Laboratory Manual” (1982): “DNA Cloning: A Practical Approach,” Volumes I and II (D. N. Glover, ed., 1985); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Nucleic Acid Hybridization” (B. D. Hames & S. J. Higgins, eds., 1985); “Transcription and Translation” (B. D. D.
- nucleic acid sequences of various microRNAs are available in the art.
- the nucleic acid sequence of miR-126 is depicted in SEQ ID NO: 1.
- SEQ ID NO: 1 is a sequence of human miR-126 (residues 1-22)
- nucleic acid sequence of a target sequence of miR-126 is depicted in SEQ ID NO: 2.
- SEQ ID NO: 2 is a nucleic acid target sequence of human miR-126 (residues 1-22)
- CGCATTATTACTCACGGTACGA One of skill in the art can determine the complementary sequence of a nucleic acid target sequence of a microRNA, such as, but not limited to, SEQ ID NO. 2.
- One skilled in the art can obtain a protein in several ways, which include, but are not limited to, isolating the protein via biochemical means or expressing a nucleotide sequence encoding the protein of interest by genetic engineering methods.
- a protein is encoded by a nucleic acid (including, for example, genomic DNA, complementary DNA (cDNA), synthetic DNA, as well as any form of corresponding RNA).
- a nucleic acid including, for example, genomic DNA, complementary DNA (cDNA), synthetic DNA, as well as any form of corresponding RNA.
- cDNA complementary DNA
- synthetic DNA as well as any form of corresponding RNA.
- the proteins of the invention can be obtained from various sources and can be produced according to various techniques known in the art.
- a nucleic acid that encodes a protein can be obtained by screening DNA libraries, or by amplification from a natural source.
- a protein can be a fragment or portion thereof.
- nucleic acids encoding a protein can be produced via recombinant DNA technology and such recombinant nucleic acids can be prepared by conventional techniques, including chemical synthesis, genetic engineering, enzymatic techniques, or a combination thereof.
- a p27 protein is the polypeptide encoded by the nucleic acid having the nucleotide sequence shown in SEQ ID NO: 4.
- An example of an p27 polypeptide has the amino acid sequence shown in SEQ ID NO: 3.
- the polypeptide sequence of human p27 is depicted in SEQ ID NO: 3.
- the nucleotide sequence of human p27 is shown in SEQ ID NO: 4.
- Sequence information related to p27 is accessible in public databases by GenBank Accession numbers NM — 004064 (for nucleic acid) and NP — 004055 (for protein).
- SEQ ID NO: 3 is the human wild type amino acid sequence corresponding to p27 (residues 1-198)
- SEQ ID NO: 4 is the human wild type nucleic acid sequence corresponding to p27 (residues 1-2413)
- p27 is a protein encoded by the CDKN1B gene.
- p27 is a cyclin-dependent kinase inhibitor, and is also known as p27 Kip1 . It is a member of the kinase inhibitor protein (KIP) family.
- KIP kinase inhibitor protein
- Protein variants can include amino acid sequence modifications.
- amino acid sequence modifications fall into one or more of three classes: substitutional, insertional or deletional variants.
- Insertions can include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
- Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture.
- substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis.
- Amino acid substitutions can be single residues, but can occur at a number of different locations at once.
- insertions can be on the order of about from 1 to about 10 amino acid residues, while deletions can range from about 1 to about 30 residues.
- Deletions or insertions can be made in adjacent pairs (for example, a deletion of about 2 residues or insertion of about 2 residues).
- Substitutions, deletions, insertions, or any combination thereof can be combined to arrive at a final construct.
- the mutations cannot place the sequence out of reading frame and should not create complementary regions that can produce secondary mRNA structure.
- Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place.
- Substantial changes in function or immunological identity are made by selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain.
- the substitutions that can produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g.
- an electropositive side chain e.g., lysyl, arginyl, or histidyl
- an electronegative residue e.g., glutamyl or aspartyl
- variations in the amino acid sequences of proteins are provided by the present invention.
- the variations in the amino acid sequence can be when the sequence maintains at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% identity to SEQ ID NO: 3, or any other amino acid sequence of interest.
- conservative amino acid replacements can be utilized.
- Conservative replacements are those that take place within a family of amino acids that are related in their side chains, wherein the interchangeability of residues have similar side chains.
- amino acids are generally divided into families: (1) acidic amino acids are aspartate, glutamate: (2) basic amino acids are lysine, arginine, histidine; (3) non-polar amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and (4) uncharged polar amino acids are glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.
- the hydrophilic amino acids include arginine, asparagine, aspartate, glutamine, glutamate, histidine, lysine, serine, and threonine.
- the hydrophobic amino acids include alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine.
- Other families of amino acids include (i) a group of amino acids having aliphatic-hydroxyl side chains, such as serine and threonine; (ii) a group of amino acids having amide-containing side chains, such as asparagine and glutamine; (iii) a group of amino acids having aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; (iv) a group of amino acids having aromatic side chains, such as phenylalanine, tyrosine, and tryptophan; and (v) a group of amino acids having sulfur-containing side chains, such as cysteine and methionine.
- Useful conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine valine, glutamic-aspartic, and asparagine-glutamine.
- substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
- Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr).
- Deletions of cysteine or other labile residues also can be desirable.
- Deletions or substitutions of potential proteolysis sites, e.g. Arg is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.
- a number of expression vectors can be selected. For example, when a large quantity of a protein encoded by a gene is needed for the induction of antibodies, vectors which direct high level expression of proteins that are readily purified can be used.
- Non-limiting examples of such vectors include multifunctional E. coli cloning and expression vectors such as BLUESCRIPT (Stratagene).
- pIN vectors or pGEX vectors also can be used to express foreign polypeptide molecules as fusion proteins with glutathione S-transferase (GST).
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
- Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
- sequences encoding a protein can be driven by any of a number of promoters.
- viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV.
- plant promoters such as the small subunit of RUBISCO or heat shock promoters, can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.
- An insect system also can be used to express proteins.
- Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
- Sequences encoding a polypeptide can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter.
- Successful insertion of nucleic acid sequences such as a sequence corresponding to a gene of interest, will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein.
- the recombinant viruses can then be used to infect S. frugiperda cells or Trichoplusia larvae in which the protein or a variant thereof can be expressed.
- An expression vector can include a nucleotide sequence that encodes a polypeptide linked to at least one regulatory sequence in a manner allowing expression of the nucleotide sequence in a host cell.
- a number of viral-based expression systems can be used to express a protein or a variant thereof in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding a protein can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion into a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which expresses a protein in infected host cells. Transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can also be used to increase expression in mammalian host cells.
- RSV Rous sarcoma virus
- regulatory sequences are well known in the art, and can be selected to direct the expression of a protein or polypeptide of interest in an appropriate host cell as described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).
- regulatory sequences include: polyadenylation signals, promoters (such as CMV, ASV, SV40, or other viral promoters such as those derived from bovine papilloma, polyoma, and Adenovirus 2 viruses (Fiers, et al., 1973 , Nature 273:113; Hager G L, et al., Curr Opin Genet Dev, 2002, 12(2):137-41) enhancers, and other expression control elements.
- promoters such as CMV, ASV, SV40, or other viral promoters such as those derived from bovine papilloma, polyoma, and Adenovirus 2 viruses (Fiers, et al., 1973 , Nature 273:
- Enhancer regions which are those sequences found upstream or downstream of the promoter region in non-coding DNA regions, are also known in the art to be important in optimizing expression. If needed, origins of replication from viral sources can be employed, such as if a prokaryotic host is utilized for introduction of plasmid DNA. However, in eukaryotic organisms, chromosome integration is a common mechanism for DNA replication.
- Suitable promoters for expressing RNA from a plasmid include, e.g., the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art.
- Recombinant plasmids can comprise inducible or regulatable promoters for expression of the RNA in cells (such as, but not limited to, vascular smooth muscle cells or endothelial cells).
- a nucleic acid encoding a gene such as, but not limited to, a p27 gene, and one or more target sequences for a microRNA, such as, but not limited to, miR-126 (comprising one or more sequences of SEQ ID NO: 2) can be placed under the control of the CMV intermediate-early promoter, whereby the nucleic acid sequences encoding the p27 gene are located 3′ of the promoter, so that the promoter can initiate transcription of the miRNA gene product coding sequences.
- a gene that encodes a selectable marker (for example, resistance to antibiotics or drugs, such as ampicillin, neomycin, G418, and hygromycin) can be introduced into host cells along with the gene of interest in order to identify and select clones that stably express a gene encoding a protein of interest.
- the gene encoding a selectable marker can be introduced into a host cell on the same plasmid as the gene of interest or can be introduced on a separate plasmid. Cells containing the gene of interest can be identified by drug selection wherein cells that have incorporated the selectable marker gene will survive in the presence of the drug. Cells that have not incorporated the gene for the selectable marker die. Surviving cells can then be screened for the production of the desired protein molecule.
- a small fraction of cells can integrate introduced DNA into their genomes.
- the expression vector and transfection method utilized can be factors that contribute to a successful integration event.
- a vector containing DNA encoding a protein of interest is stably integrated into the genome of eukaryotic cells (for example mammalian cells, such as, but not limited to, vascular smooth muscle cells or endothelial cells), resulting in the stable expression of transfected genes.
- An exogenous nucleic acid sequence can be introduced into a cell (such as a mammalian cell, either a primary or secondary cell) by homologous recombination as disclosed in U.S. Pat. No. 5,641,670, the contents of which are herein incorporated by reference.
- Nucleic acid vectors such as plasmids, suitable for expressing genes of interest and target sequences for microRNAs, methods for inserting nucleic acid sequences into the plasmid to express the gene of interest, and methods of delivering the recombinant vectors to cells of interest are well-established and practiced in the art. See, for example, Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat. Biotechnol, 20:446-448; Brummelkamp et al. (2002). Science 296:550-553; Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al. (2002), Genes Dev.
- Genes of interest and target sequences for microRNAs can also be expressed from recombinant viral vectors.
- the RNA expressed from the recombinant viral vectors can either be isolated from cultured cell expression systems by standard techniques, or can be expressed directly in mammalian cells (for example, vascular smooth muscle cells or endothelial cells).
- the recombinant viral vectors can comprise sequences that encode the gene of interest and any suitable promoter for expressing the RNA sequences.
- Vectors can also comprise inducible or regulatable promoters for expression of the gene of interest in cells, such as mammalian cells.
- suitable promoters include the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is practiced by those of ordinary skill in the art.
- Any viral vector that can harbor the nucleotide sequences for the gene of interest and the one or more target sequences for a microRNA of the invention can be used.
- Non-limiting examples of such vectors include: vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g., lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like.
- the tropism of the viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.
- lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like.
- VSV vesicular stomatitis virus
- AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes.
- An AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2.
- This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector.
- Techniques for constructing AAV vectors which express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz J. E. et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.
- Recombinant viral vectors suitable for expressing the gene of interest and the one or more target sequences for a microRNA of the invention methods for inserting nucleic acid sequences for expressing genes of interest in the vector, methods of delivering the viral vector to cells of interest, and recovery of the expressed nucleic acid molecules and proteins are within the skill in the art. See, for example, Dornburg (1995), Gene Therap. 2:301-310; Eglitis (1988), Biotechniques 6:608-614; Miller (1990), Hum. Gene Therap. 1:5-14; and Anderson (1998), Nature 392:25-30, the entire disclosures of which are herein incorporated by reference.
- Useful viral vectors can be those derived from AV and AAV.
- a suitable AV vector for expressing a nucleic acid molecule of the invention is described in Xia et al. (2002), Nat. Biotech. 20:1006-1010, the entire disclosure of which is herein incorporated by reference.
- Methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski et al. (1987), J. Virol. 61:3096-3101; Fisher et al. (1996). J. Virol. 70:520-532; Samulski et al. (1989), J. Virol. 63:3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788: and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.
- a eukaryotic expression vector can be used to transfect cells in order to produce proteins encoded by nucleotide sequences of the vector.
- Mammalian cells such as, but not limited to, vascular smooth muscle cells or endothelial cells
- an expression vector for example, one that contains a gene encoding a p27 protein or polypeptide
- a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed polypeptide encoded by a gene, such as a p27 gene, in the desired fashion.
- modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
- Post-translational processing which cleaves a “prepro” form of the polypeptide also can be used to facilitate correct insertion, folding and/or function.
- Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC: 10801 University Boulevard, Manassas, Va. 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.
- ATCC American Type Culture Collection
- An exogenous nucleic acid can be introduced into a cell via a variety of techniques known in the art, such as lipofection, microinjection, calcium phosphate or calcium chloride precipitation. DEAE-dextran-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest (such as cells of the end bulb of a hair follicle, for example dermal papilla cells or dermal sheath cells). Other transfection methods also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- Cells that will be genetically engineered can be primary and secondary cells obtained from various tissues, and include cell types which can be maintained and propagated in culture.
- Vertebrate tissue can be obtained by methods known to one skilled in the art, such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest.
- a mixture of primary cells can be obtained from the tissue, using methods readily practiced in the art, such as explanting or enzymatic digestion (for examples using enzymes such as pronase, trypsin, collagenase, elastase dispase, and chymotrypsin).
- Biopsy methods have also been described in United States Patent Application Publication 2004/0057937 and PCT application publication WO 2001/32840, and are hereby incorporated by reference.
- Primary cells can be acquired from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells can also be obtained from a donor, other than the recipient, of the same species. The cells can also be obtained from another species (for example, rabbit, cat, mouse, rat, sheep, goat, dog, horse, cow, bird, or pig). Primary cells can also include cells from an isolated vertebrate tissue source grown attached to a tissue culture substrate (for example, flask or dish) or grown in a suspension; cells present in an explant derived from tissue; both of the aforementioned cell types plated for the first time; and cell culture suspensions derived from these plated cells.
- tissue culture substrate for example, flask or dish
- Secondary cells can be plated primary cells that are removed from the culture substrate and replated, or passaged, in addition to cells from the subsequent passages. Secondary cells can be passaged one or more times. These primary or secondary cells can contain expression vectors having a gene that encodes a protein of interest (for example, a p27 protein or polypeptide).
- nucleic acids into viable cells can be effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., lentivirus, adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments).
- viral vectors e.g., lentivirus, adenovirus, adeno-associated virus, or a retrovirus
- physical DNA transfer methods e.g., liposomes or chemical treatments.
- Non-limiting techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, and the calcium phosphate precipitation method (see, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp. 25-20 (1998)).
- a nucleic acid or a gene encoding a polypeptide of the invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression).
- Cells may also be cultured ex vivo in the presence of therapeutic compositions of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
- Nucleic acids can be inserted into vectors and used as gene therapy vectors.
- viruses have been used as gene transfer vectors, including papovaviruses, e.g., SV40 (Madzak et al., (1992) J Gen Virol. 73(Pt 6):1533-6), adenovirus (Berkner (1992) Curr Top Microbiol Immunol. 158:39-66; Berkner (1988) Biotechniques, 6(7):616-29; Gorziglia and Kapikian (1992) J Virol. 66(7):4407-12; Quantin et al., (1992) Proc Natl Acad Sci USA.
- herpesviruses including HSV and EBV (Margolskee (1992) Curr Top Microbhiol Immunol. 158:67-95; Johnson et al., (1992) Brain Res Mol Brain Res. 12(1-3):95-102: Fink et al., (1992) Hum Gene Ther. 3(1):11-9: Breakefield and Geller (1987) Mol Neurobiol. 1(4):339-71; Freese et al., (1990) Biochem Pharmacol. 40(10):2189-99), and retroviruses of avian (Bandyopadhyay and Temin (1984) Mol Cell Biol.
- Non-limiting examples of in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors (see U.S. Pat. No. 5,252,479, which is incorporated by reference in its entirety) and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11:205-210 (1993), incorporated entirely by reference).
- viral typically retroviral
- viral coat protein-liposome mediated transfection Dzau et al., Trends in Biotechnology 11:205-210 (1993), incorporated entirely by reference.
- naked DNA vaccines are generally known in the art; see Brower, Nature Biotechnology, 16:1304-1305 (1998), which is incorporated by reference in its entirety.
- Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No.
- the pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
- the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
- Various culturing parameters can be used with respect to the host cell being cultured.
- Appropriate culture conditions for mammalian cells are well known in the art (Cleveland W L, et al., J Immunol Methods, 1983, 56(2): 221-234) or can be determined by the skilled artisan (see, for example, Animal Cell Culture: A Practical Approach 2nd Ed., Rickwood, D. and Hames, B. D., eds. (Oxford University Press: New York, 1992)).
- Cell culturing conditions can vary according to the type of host cell selected.
- Commercially available medium can be utilized. Non-limiting examples of medium include, for example, Minimal Essential Medium (MEM, Sigma, St.
- DMEM Dulbecco's Modified Eagles Medium
- Ham's F10 Medium Sigma
- HyClone cell culture medium HyClone, Logan, Utah
- RPMI-1640 Medium Sigma
- CD-CHO Medium Invitrogen, Carlsbad, Calif.
- the cell culture media can be supplemented as necessary with supplementary components or ingredients, including optional components, in appropriate concentrations or amounts, as necessary or desired.
- Cell culture medium solutions provide at least one component from one or more of the following categories: (1) an energy source, usually in the form of a carbohydrate such as glucose; (2) all essential amino acids, and usually the basic set of twenty amino acids plus cysteine; (3) vitamins and/or other organic compounds required at low concentrations; (4) free fatty acids or lipids, for example linoleic acid; and (5) trace elements, where trace elements are defined as inorganic compounds or naturally occurring elements that can be required at very low concentrations, usually in the micromolar range.
- the medium also can be supplemented electively with one or more components from any of the following categories: (1) salts, for example, magnesium, calcium, and phosphate: (2) hormones and other growth factors such as, serum, insulin, transferrin, and epidermal growth factor: (3) protein and tissue hydrolysates, for example peptone or peptone mixtures which can be obtained from purified gelatin, plant material, or animal byproducts; (4) nucleosides and bases such as, adenosine, thymidine, and hypoxanthine; (5) buffers, such as HEPES: (6) antibiotics, such as gentamycin or ampicillin; (7) cell protective agents, for example pluronic polyol; and (8) galactose.
- soluble factors can be added to the culturing medium.
- the mammalian cell culture that can be used with the present invention is prepared in a medium suitable for the type of cell being cultured.
- the cell culture medium can be any one of those previously discussed (for example, MEM) that is supplemented with serum from a mammalian source (for example, fetal bovine serum (FBS)).
- the medium can be a conditioned medium to sustain the growth of mammalian cells.
- cells are grown in a suspension culture (for example, a three-dimensional culture such as a hanging drop culture) in the presence of an effective amount of enzyme, wherein the enzyme substrate is an extracellular matrix molecule in the suspension culture.
- the enzyme can be a hyaluronidase.
- a suspension culture is a type of culture wherein cells, or aggregates of cells multiply while suspended in liquid medium.
- a suspension culture comprising mammalian cells can be used for the maintenance of cell types that do not adhere or to enable cells to manifest specific cellular characteristics that are not seen in the adherent form.
- Some types of suspension cultures can include three-dimensional cultures or a hanging drop culture.
- a hanging-drop culture is a culture in which the material to be cultivated is inoculated into a drop of fluid attached to a flat surface (such as a coverglass, glass slide, Petri dish, flask, and the like), and can be inverted over a hollow surface. Cells in a hanging drop can aggregate toward the hanging center of a drop as a result of gravity.
- cells cultured in the presence of a protein that degrades the extracellular matrix (such as collagenase, chondroitinase, hyaluronidase, and the like) will become more compact and aggregated within the hanging drop culture, for degradation of the ECM will allow cells to become closer in proximity to one another since less of the ECM will be present.
- a protein that degrades the extracellular matrix such as collagenase, chondroitinase, hyaluronidase, and the like
- Three-dimensional cultures can be formed from agar (such as Gey's Agar), hydrogels (such as matrigel, agarose, and the like; Lee et al., (2004) Biomaterials 25: 2461-2466) or polymers that are cross-linked.
- These polymers can comprise natural polymers and their derivatives, synthetic polymers and their derivatives, or a combination thereof.
- Natural polymers can be anionic polymers, cationic polymers, amphipathic polymers, or neutral polymers.
- anionic polymers can include hyaluronic acid, alginic acid (alginate), carageenan, chondroitin sulfate, dextran sulfate, and pectin.
- cationic polymers include but are not limited to, chitosan or polylysine.
- amphipathic polymers can include, but are not limited to collagen, gelatin, fibrin, and carboxymethyl chitin.
- neutral polymers can include dextran, agarose, or pullulan.
- Cells suitable for culturing according to methods of the invention can harbor introduced expression vectors, such as plasmids.
- the expression vector constructs can be introduced via transformation, microinjection, transfection, lipofection, electroporation, or infection.
- the expression vectors can contain coding sequences, or portions thereof, encoding the proteins for expression and production.
- Expression vectors containing sequences encoding the produced proteins and polypeptides, as well as the appropriate transcriptional and translational control elements, can be generated using methods well known to and practiced by those skilled in the art. These methods include synthetic techniques, in vitro recombinant DNA techniques, and in vivo genetic recombination which are described in J.
- a polypeptide molecule encoded by a gene such as a p27 gene, or a variant thereof, can be obtained by purification from human cells expressing a protein or polypeptide encoded by a p27 gene via in vitro or in vivo expression of a nucleic acid sequence encoding a p27 protein or polypeptide: or by direct chemical synthesis.
- Host cells which contain a nucleic acid encoding a p27 protein or polypeptide, and which subsequently express a protein encoded by a p27 gene can be identified by various procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a nucleic acid encoding a p27 protein or polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments of nucleic acids encoding a p27 protein or polypeptide.
- a fragment of a nucleic acid of a p27 gene can encompass any portion of at least about 8 consecutive nucleotides of SEQ ID NO: 4.
- the fragment can comprise at least about 10 consecutive nucleotides, at least about 15 consecutive nucleotides, at least about 20 consecutive nucleotides, or at least about 30 consecutive nucleotides of SEQ ID NO: 4.
- Fragments can include all possible nucleotide lengths between about 8 and about 100 nucleotides, for example, lengths between about 15 and about 100 nucleotides, or between about 20 and about 100 nucleotides.
- Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a polypeptide encoded by a p27 gene to detect transformants which contain a nucleic acid encoding a p27 protein or polypeptide.
- Protocols for detecting and measuring the expression of a polypeptide encoded by a gene, such as a p27 gene, using either polyclonal or monoclonal antibodies specific for the polypeptide are well established.
- Non-limiting examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- FACS fluorescence activated cell sorting
- a two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a polypeptide encoded by a gene, such as a p27 gene, can be used, or a competitive binding assay can be employed.
- Labeling and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays.
- Methods for producing labeled hybridization or PCR probes for detecting sequences related to nucleic acid sequences encoding a protein, such as, but not limited to, p27 include, but are not limited to, oligo labeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
- nucleic acid sequences encoding a polypeptide encoded by a gene, such as a p27 gene can be cloned into a vector for the production of an mRNA probe.
- RNA probes are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, and/or magnetic particles.
- Host cells transformed with a nucleic acid sequence encoding a polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture.
- the polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used.
- Expression vectors containing a nucleic acid sequence encoding a polypeptide can be designed to contain signal sequences which direct secretion of soluble polypeptide molecules encoded by a gene, such as, but not limited to, p27, or a variant thereof, through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound a polypeptide molecule encoded by a p27 gene or a variant thereof.
- purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.).
- cleavable linker sequences i.e., those specific for Factor Xa or enterokinase (Invitrogen, San Diego, Calif.)
- cleavable linker sequences i.e., those specific for Factor Xa or enterokinase (Invitrogen, San Diego, Calif.)
- One such expression vector provides for expression of a fusion protein containing a polypeptide encoded by a p27 gene, for example, and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by immobilized metal ion affinity chromatography, while the enterokinase cleavage site provides a means for purifying the polypeptide encoded by a p27 gene.
- a p27 polypeptide can be purified from any human or non-human cell which expresses the polypeptide, including those which have been transfected with expression constructs that express a p27 protein.
- a purified p27 protein can be separated from other compounds which normally associate with a protein encoded by a p27 gene in the cell, such as certain proteins, carbohydrates, or lipids, using methods practiced in the art. Non-limiting methods include size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.
- Nucleic acid sequences comprising a gene, such as, but not limited to, a p27 gene, that encodes a polypeptide can be synthesized, in whole or in part, using chemical methods known in the art.
- a polypeptide, such as, but not limited to, p27 can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer).
- fragments of p27 polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.
- a fragment of a nucleic acid sequence that comprises a p27 gene can encompass any portion of at least about 8 consecutive nucleotides of SEQ ID NO: 4.
- the fragment can comprise at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, or at least about 30 nucleotides of SEQ ID NO: 4.
- Fragments include all possible nucleotide lengths between about 8 and about 100 nucleotides, for example, lengths between about 15 and about 100 nucleotides, or between about 20 and about 100 nucleotides.
- nucleic acid sequences such as, but not limited to, microRNA target sequences
- a fragment of a nucleic acid sequence that comprises microRNA target sequences can encompass any portion of at least about 4 consecutive nucleotides of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- the fragment can comprise at least about 6 nucleotides, at least about 8 nucleotides, at least about 10 nucleotides, or at least about 12 nucleotides, at least about 14 nucleotides, at least about 16 nucleotides of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. Fragments include all possible nucleotide lengths between about 4 and about 40 nucleotides, for example, lengths between about 10 and about 30 nucleotides, or between about 10 and about 20 nucleotides.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences can encompass one or more nucleic acid sequences of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses one nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses two nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses three nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses four nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses 5, 6, 7, 8, 9, 10, or more nucleic acid sequences of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- a synthetic peptide can be substantially purified via high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- the composition of a synthetic polypeptide of can be confirmed by amino acid analysis or sequencing. Additionally, any portion of an amino acid sequence comprising a protein encoded by a gene can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.
- the present invention provides for a composition comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the composition is a pharmaceutical composition.
- the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical.
- the nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises a second gene of interest.
- the second gene of interest is a human gene.
- the second gene of interest is a non-human gene.
- the second gene of interest is p53.
- the second gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the second gene of interest is an antithrombotic gene.
- the second gene of interest is an anti-inflammatory gene.
- the second gene of interest is ENTPD1, TFPI or PTGIS.
- the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the vector comprises one target sequence.
- the vector comprises two target sequences.
- the vector comprises three target sequences.
- the vector comprises four target sequences.
- the vector comprises five target sequences.
- the vector comprises six target sequences.
- the vector comprises seven target sequences.
- the vector comprises eight target sequences.
- the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the viral vector is a lentiviral vector.
- the vector is a retroviral vector.
- adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12).
- the vector is an adeno-associated vector.
- adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2).
- lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2.
- retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV).
- oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- MMV Murine Leukemia Virus
- SNV Spleen Necrosis Virus
- RSV Rous sarcoma virus
- AMV Avian Leukosis Virus
- the invention provides a method of treating or preventing a cardiovascular disease in a subject in need thereof, the method comprising administering a nucleic acid vector to the subject, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical.
- the nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- the vector comprises a second gene of interest.
- the second gene of interest is a human gene.
- the second gene of interest is a non-human gene.
- the second gene of interest is p53.
- the second gene of interest is a tumor suppressor gene.
- a tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1. BRAC2, or DPC4.
- the second gene of interest is an antithrombotic gene.
- the second gene of interest is an anti-inflammatory gene.
- the second gene of interest is ENTPD1, TFPI or PTGIS.
- the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- the vector comprises one target sequence.
- the vector comprises two target sequences.
- the vector comprises three target sequences.
- the vector comprises four target sequences.
- the vector comprises five target sequences.
- the vector comprises six target sequences.
- the vector comprises seven target sequences.
- the vector comprises eight target sequences.
- the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- the nucleic acid vector is a viral vector.
- the viral vector is an adenoviral vector.
- the viral vector is a lentiviral vector.
- the vector is a retroviral vector.
- adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12).
- the vector is an adeno-associated vector.
- adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2).
- lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2.
- retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV).
- oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- MMV Murine Leukemia Virus
- SNV Spleen Necrosis Virus
- RSV Rous sarcoma virus
- AMV Avian Leukosis Virus
- the nucleic acid vector is delivered into a cell of the subject. Delivery can be conducted by any method known to one of skill in the art, including, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- the cell expresses the microRNA. In another embodiment, the cell does not express the microRNA.
- the gene of interest is not expressed in the cell. In another embodiment, the gene of interest is expressed in the cell. In one embodiment, the second gene of interest is not expressed in the cell. In another embodiment, the second gene of interest is expressed in the cell.
- the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell. In further embodiments, the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell.
- Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- the cell is a cancer cell.
- the cancer can be, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- the cardiovascular disease is coronary artery disease. In another embodiment, the cardiovascular disease is atherosclerotic coronary artery disease. In further embodiments, the cardiovascular disease includes, but is not limited to, coronary vasospasm, restenosis, myocardial ischemia, stent induced injury, stent thrombosis, cardiomyopathy, hypertensive heart disease, heart failure, cor pulmonale, cardiac dysrhythmias, inflammatory heart disease, valvular heart disease, peripheral arterial disease, cerebrovascular disease, congenital heart disease, atherosclerosis, arterial injury and rheumatic heart disease.
- the methods of the invention can also be used for other vascular conditions, such as vascular access failure, for example, in hemodialysis.
- Nucleic acid vectors of the invention can be administered to the subject once (e.g., as a single injection or deposition). Alternatively, nucleic acid vectors of the invention can be administered once or twice daily to a subject in need thereof for a period of from about two to about twenty-eight days, or from about seven to about ten days. Nucleic acid vectors of the invention can also be administered once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof. Furthermore, nucleic acid vectors of the invention can be co-administrated with another therapeutic. Where a dosage regimen comprises multiple administrations, the effective amount of the nucleic acid vectors administered to the subject can comprise the total amount of the nucleic acid vectors administered over the entire dosage regimen.
- Nucleic acid vectors of the invention can be administered to a subject by any means suitable for delivering the nucleic acid vectors to cells of the subject.
- nucleic acid vectors can be administered by methods suitable to transfect cells. Transfection methods for eukaryotic cells are well known in the art, and include direct injection of a nucleic acid into the nucleus or pronucleus of a cell; electroporation; liposome transfer or transfer mediated by lipophilic materials; receptor mediated nucleic acid delivery, bioballistic or particle acceleration; calcium phosphate precipitation, and transfection mediated by viral vectors.
- the nucleic acid vectors of the invention may be administered to a subject in an amount effective to treat or prevent a cardiovascular disease, such as, but not limited to, coronary artery disease.
- a cardiovascular disease such as, but not limited to, coronary artery disease.
- One of skill in the art can readily determine what will be an effective amount of the nucleic acid vectors of the invention to be administered to a subject, taking into account whether the nucleic acid vectors are being used prophylactically or therapeutically, and taking into account other factors such as the age, weight and sex of the subject, any other drugs that the subject may be taking, any allergies or contraindications that the subject may have, and the like.
- an effective amount can be determined by the skilled artisan using known procedures, including analysis of titration curves established in vitro or in vivo.
- one of skill in the art can determine the effective dose from performing pilot experiments in suitable animal model species and scaling the doses up or down depending on the subjects weight etc. Effective amounts can also be determined by performing clinical trials in individuals of the same species as the subject, for example starting at a low dose and gradually increasing the dose and monitoring the effects on a metabolic disorder, or coronary artery disease. Appropriate dosing regimens can also be determined by one of skill in the art without undue experimentation, in order to determine, for example, whether to administer the agent in one single dose or in multiple doses, and in the case of multiple doses, to determine an effective interval between doses.
- a therapeutically effective dose of a nucleic acid vector of the invention that treats or prevents a cardiovascular disease, such as, but not limited to, coronary artery disease can depend upon a number of factors known to those of ordinary skill in the art.
- the dose(s) of the nucleic acid vectors can vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition comprising nucleic acid vectors is to be administered, if applicable, and the effect which the practitioner desires the nucleic acid vectors to have upon the target of interest. These amounts can be readily determined by a skilled artisan.
- any of the therapeutic applications described herein can be applied to any subject in need of such therapy, including, for example, a mammal such as a dog, a cat, a cow, a horse, a rabbit, a monkey, a pig, a sheep, a goat, or a human.
- a mammal such as a dog, a cat, a cow, a horse, a rabbit, a monkey, a pig, a sheep, a goat, or a human.
- compositions of this invention can be formulated and administered to reduce the symptoms associated with a cardiovascular disease, such as, but not limited to, coronary artery disease, by any means that produces contact of the active ingredient with the agent's site of action in the body of a subject, such as a human or animal (e.g., a dog, cat, or horse). They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
- a cardiovascular disease such as, but not limited to, coronary artery disease
- compositions for use in accordance with the invention can be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
- the therapeutic compositions of the invention can be formulated for a variety of routes of administration, including systemic or localized administration. Techniques and formulations generally can be found in Remmington's Pharmaceutical Sciences , Meade Publishing Co., Easton, Pa. (20 th Ed., 2000), the entire disclosure of which is herein incorporated by reference.
- an injection is useful, including intramuscular, intravenous, intraperitoneal, and subcutaneous.
- the therapeutic compositions of the invention can be formulated in liquid solutions, for example in physiologically compatible buffers such as Hank's solution or Ringer's solution.
- compositions of the present invention can be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
- Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. These pharmaceutical formulations include formulations for human and veterinary use.
- a pharmaceutically acceptable carrier can comprise any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent that is compatible with the active ingredient can be used. Supplementary active compounds can also be incorporated into the compositions.
- the invention also provides for a kit that comprises a pharmaceutically acceptable carrier and one or more nucleic acid vector(s) of the invention packaged with instructions for use.
- a pharmaceutical composition containing nucleic acid vectors of the invention can be administered in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed herein.
- the compositions can be administered alone or in combination with at least one other agent, such as a stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
- a stabilizing compound which can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
- the compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor EMTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of injectable compositions can be brought about by incorporating an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the nucleic acid vectors of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the nucleic acid vectors into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated herein.
- examples of useful preparation methods are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the nucleic acid vectors are formulated into ointments, salves, gels, or creams as generally known in the art.
- the nucleic acid vectors can be applied via transdermal delivery systems, which slowly releases the nucleic acid vectors for percutaneous absorption.
- Permeation enhancers can be used to facilitate transdermal penetration of the active factors in the conditioned media.
- Transdermal patches are described in for example, U.S. Pat. No. 5,407,713; U.S. Pat. No. 5,352,456; U.S. Pat. No. 5,332,213; U.S. Pat. No. 5,336,168; U.S. Pat. No. 5,290,561; U.S. Pat. No. 5,254,346; U.S. Pat. No. 5,164,189; U.S. Pat. No. 5,163,899; U.S. Pat. No. 5,088,977; U.S. Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No. 4,921,475.
- nucleic acid vectors are not restricted to a single route, but may encompass administration by multiple routes.
- exemplary administrations by multiple routes include, among others, a combination of intradermal and intramuscular administration, or intradermal and subcutaneous administration. Multiple administrations may be sequential or concurrent. Other modes of application by multiple routes will be apparent to the skilled artisan.
- the nucleic acid vectors of the invention may be formulated into compositions for administration to subjects for the treatment and/or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease.
- Such compositions may comprise the nucleic acid vectors of the invention in admixture with one or more pharmaceutically acceptable diluents and/or carriers and optionally one or more other pharmaceutically acceptable additives.
- the pharmaceutically-acceptable diluents and/or carriers and any other additives must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the subject to whom the composition will be administered.
- nucleic acid vectors of the invention into compositions suitable for administration to subjects, such as human subjects, for example using the teaching a standard text such as Remington's Pharmaceutical Sciences, 18th ed, (Mack Publishing Company: Easton, Pa., 1990), pp. 1635-36), and by taking into account the selected route of delivery.
- diluents and/or carriers and/or other additives examples include, but are not limited to, water, glycols, oils, alcohols, aqueous solvents, organic solvents, DMSO, saline solutions, physiological buffer solutions, peptide carriers, starches, sugars, preservatives, antioxidants, coloring agents, pH buffering agents, granulating agents, lubricants, binders, disintegrating agents, emulsifiers, binders, excipients, extenders, glidants, solubilizers, stabilizers, surface active agents, suspending agents, tonicity agents, viscosity-altering agents, carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, powders, saline, sodium alginate.
- diluents and/or carriers and/or other additives used can be varied taking into account the nature of the active agents used (for example the solubility and stability of the active agents), the route of delivery (e.g. oral, parenteral, etc.), whether the agents are to be delivered over an extended period (such as from a controlled-release capsule), whether the agents are to be co-administered with other agents, and various other factors.
- the route of delivery e.g. oral, parenteral, etc.
- an extended period such as from a controlled-release capsule
- agents are to be co-administered with other agents
- compositions of the invention may be administered to a subject by any suitable method that allows the agent to exert its effect on the subject in vivo.
- the compositions may be administered to the subject by known procedures including, but not limited to, by oral administration, sublingual or buccal administration, parenteral administration, transdermal administration, via inhalation, via nasal delivery, vaginally, rectally, and intramuscularly.
- the compositions of the invention may be administered parenterally, or by epifascial, intracapsular, intracutaneous, subcutaneous, intradermal, intrathecal, intramuscular, intraperitoneal, intrasternal, intravascular, intravenous, parenchymatous, or sublingual delivery.
- nucleic acid vectors of the invention are administered to the subject by way of delivery directly to the heart tissue, such as by way of a catheter inserted into, or in the proximity of the subject's heart, or by using delivery vehicles capable of targeting the drug to the heart.
- the nucleic acid vectors of the invention may be conjugated to or administered in conjunction with an agent that is targeted to the heart, such as an antibody or antibody fragment.
- the nucleic acid vectors of the invention are administered to the subject by way of delivery directly to the tissue of interest, such as by way of a catheter inserted into, or in the proximity of the subject's tissue of interest, or by using delivery vehicles capable of targeting the nucleic acid vectors to the muscle, such as an antibody or antibody fragment.
- a formulation of the nucleic acid vectors of the invention may be presented as capsules, tablets, powders, granules, or as a suspension or solution.
- the formulation may contain conventional additives, such as lactose, mannitol, cornstarch or potato starch, binders, crystalline cellulose, cellulose derivatives, acacia, cornstarch, gelatins, disintegrators, potato starch, sodium carboxymethylcellulose, dibasic calcium phosphate, anhydrous or sodium starch glycolate, lubricants, and/or or magnesium stearate.
- the nucleic acid vectors of the invention may be combined with a sterile aqueous solution that is isotonic with the blood of the subject.
- a sterile aqueous solution that is isotonic with the blood of the subject.
- Such a formulation may be prepared by dissolving the active ingredient in water containing physiologically-compatible substances, such as sodium chloride, glycine and the like, and having a buffered pH compatible with physiological conditions, so as to produce an aqueous solution, then rendering the solution sterile.
- the formulation may be presented in unit or multi-dose containers, such as sealed ampoules or vials.
- the formulation may be delivered by injection, infusion, or other means known in the art.
- the nucleic acid vectors of the invention may be combined with skin penetration enhancers, such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone and the like, which increase the permeability of the skin to the nucleic acid vectors of the invention and permit the nucleic acid vectors to penetrate through the skin and into the bloodstream.
- skin penetration enhancers such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone and the like
- the nucleic acid vectors of the invention also may be further combined with a polymeric substance, such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like, to provide the composition in gel form, which are dissolved in a solvent, such as methylene chloride, evaporated to the desired viscosity and then applied to backing material to provide a patch.
- a polymeric substance such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like
- the nucleic acid vectors of the invention are provided in unit dose form such as a tablet, capsule or single-dose injection or infusion vial.
- a nucleic acid vector of the invention can be administered to a subject either as a single agent, or in combination with one or more other agents.
- a nucleic acid vector of the invention is administered to a subject as a single agent.
- a nucleic acid vector of the invention is administered to a subject alone.
- a nucleic acid vector of the invention is administered to a subject in combination with one or more other agents.
- a nucleic acid vector of the invention may be used in combination with other agents that are used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject.
- a nucleic acid vector of the invention may be used in combination with other agents that are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject.
- a nucleic acid vector of the invention may be delivered to a subject as part of the same pharmaceutical composition or formulation containing one or more additional active agents.
- a nucleic acid vector of the invention may be delivered to a subject in a composition or formulation containing only that active agent, while one or more other agents are administered to the subject in one or more separate compositions or formulations.
- the other agents are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject.
- the other agents are used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject.
- a nucleic acid vector of the invention and the other agents that are used for the treatment or prevention of a cardiovascular disease such as, but not limited to, coronary artery disease in a subject, may be administered to the subject at the same time, or at different times.
- a nucleic acid vector of the invention and the other agents that are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease may be administered to the subject at the same time, or at different times.
- a nucleic acid vector of the invention and the other agents may be administered within minutes, hours, days, weeks, or months of each other, for example as part of the overall treatment regimen of a subject.
- a nucleic acid vector of the invention may be administered prior to the administration of other agents.
- a nucleic acid vector of the invention may be administered subsequent to the administration of other agents.
- the administration of a nucleic acid vector of the invention in combination with one or more other agents has an additive effect, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone.
- the administration of a nucleic acid vector of the invention in combination with one or more other agents has a synergistic effect, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone.
- the administration of a nucleic acid vector of the invention in combination with one or more other agents can help reduce side effects, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone.
- the nucleic acid vector of the invention is used as an adjuvant therapy. In other embodiments, the nucleic acid vector of the invention is used in combination with an adjuvant therapy.
- the invention may also be used in combination with known therapies for a cardiovascular disease.
- therapies for a cardiovascular disease include, but are not limited to, aspirin; statins, such as atorvastatin (Lipitor, Torvast), fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin (Livalo, Pitava), pravastatin (Pravachol, Selektine, Lipostat), rosuvastatin (Crestor), and simvastatin (Zocor, Lipex); nitroglycerin; angiotensin-converting enzyme (ACE) inhibitors, such as enalapril (Vasotec®), lisinopril (Zestril®, Prinvil®), ramipril (Altace®) and captopril (Capoten®); calcium channel blockers, such as verapamil (Calan®, Isoptin®); and beta-blockers, such as carved
- the invention may also be used in combination with surgical or other interventional treatment regimens used for treatment of a cardiovascular disease, such as, but not limited to, use of a device, including, but not limited to, a stent, a rapamycin-coated stent, a drug-eluting stent, a bare-metal stent, a pacemaker, an implantable cardioverter-defibrillator (ICD) or a ventricular assist device (VAD).
- a device including, but not limited to, a stent, a rapamycin-coated stent, a drug-eluting stent, a bare-metal stent, a pacemaker, an implantable cardioverter-defibrillator (ICD) or a ventricular assist device (VAD).
- ICD implantable cardioverter-defibrillator
- VAD ventricular assist device
- the subject or patient can be any animal that has or is diagnosed with a cardiovascular disease, such as, but not limited to, coronary artery disease.
- the subject or patient can be any animal that is predisposed to or is at risk of developing a cardiovascular disease, such as, but not limited to, coronary artery disease.
- the subject is a human subject.
- the subject is a rodent, such as a mouse.
- the subject is a cow, pig, sheep, goat, cat, horse, dog, and/or any other species of animal used as livestock or kept as pets.
- the subject is already suspected to have a cardiovascular disease, such as, but not limited to, coronary artery disease.
- the subject is being treated for a cardiovascular disease, such as, but not limited to, coronary artery disease, before being treated according to the methods of the invention.
- the subject is not being treated for a cardiovascular disease, such as, but not limited to, coronary artery disease, before being treated according to the methods of the invention.
- Coronary artery disease is a leading cause of death worldwide.
- DES drug-eluting stents
- EC delayed endothelial cell
- PCI Percutaneous coronary intervention
- the drugs that elute from the stent not only inhibit VSMC, but also EC proliferation and migration (5, 6), increasing the risk of late thrombosis, a rare and potentially catastrophic event that is caused by incomplete re-endothelization (1, 7).
- the ideal therapy can provide VSMC-selective anti-proliferative activity without affecting EC.
- miRs microRNAs
- a class of endogenous small non-coding RNA (8, 9) miRs regulate the expression of much of the transcriptome via degradation of their target mRNA and/or inhibiting translation
- miR-126 is expressed in a cell-specific manner (8, 10) that enabled to selectively inhibit VSMC proliferation while preserving the capability of EC to proliferate and migrate in order to re-endothelialize the vessel. Since the expression level of miR-126 is >600-fold higher in EC than in VSMC ( FIG. 2A ), this miR was selected to design a VSMC-specific therapy.
- the cyclin-dependent kinase inhibitor p27 KIP1 (p27) is known to be a potent inhibitor of cell proliferation (3).
- Different adenoviral (Ad) vectors were designed to overexpress p27 ( FIGS. 4A-C ): a CMV-GFP-p27 (Ad-p27) and a CMV-GFP-p27 containing 4 target sequences of miR-126 in its 3′UTR (Ad-p27-126TS) to selectively avoid overexpression of p27 in EC.
- Ad-GFP A CMV-GFP virus
- EC and VSMC were infected with these Ad and the expressions of GFP and p27 were assessed by immunoblotting (FIGS.
- FIG. 5A the efficiency of the infection (GFP immunostaining.
- FIG. 5B and FIGS. 4 A,B) and the integrity of the endothelium were evaluated. Since pathological and clinical studies have reported incomplete neointimal coverage after PCI leading to thrombosis (12, 13), hypercoagulability was assessed by measuring plasma levels of D-dimer (14).
- vascular reactivity assay was performed on carotid rings harvested from rats 2 weeks after vessel surgery (15).
- Carotid arteries infected with Ad-GFP displayed a blunted vasodilation response to acetylcholine, most likely due to restenosis ( FIG. 3E ).
- the Ad-p27-infected vessels also showed an impaired vasodilation response, comparable to denuded control vessels.
- Arteries infected with Ad-p27-126TS in contrast, showed a normal vasodilation response, comparable to uninjured control vessels ( FIG. 3E ).
- Ad-p27 human p27
- Ad-p27-126TS AdEasy XL Adenoviral Vector System
- p27 was amplified with primers 5′-agtcggtaccaccATGTCAAACGTGCGAGTGTCTAACGG-3′ and 5′-gatctgtacaggatccTTACGTTTGACGTCTTCTGAGGCC-3′ (start and stop codons in bold and restriction sites in lowercase) and subcloned into a carrier vector.
- Complementary oligonucleotides containing four targeting sequences for miR-126 (in bold) (5′-aattcATCGCATTATTACTCACGGTACGAAATCCGCATTATTACTCACGGT ACGAAATCCGCATTATTACTCACGGTACGAAATCCGCATTATTACTCA CGGTACGAATg-3′ and 5′-aattcATTCGTACCGTGAGTAATAATGCGGATTTCGTACCGTGAGTAATA ATGCGGAITCGTACCGTGAGTAATAATGCGGATTTCGTACCGTGAGT AATAATGCGATg-3′) were annealed and subcloned in the 3′-UTR region of p27 with EcoRI.
- p27 and p27-126TSx4 were amplified from the carrier vector with the following pairs of primers: 5′-agtcggtaccaccATGTCAAACGTGCGAGTGTCTAACGG-3′ as a sense primer for both constructs, and 5′-agtcctcgagTTACGTTTGACGTCTTCTGAGGCC-3′ and 5′-agtcctcgagaTTCGTACCGTGAGTAATAATGCGGATTTC-3′ as antisense primers for p27 and p27-126TSx4, respectively.
- PCR products were subcloned into pAdTrack-CMV shuttle vector (using Acc65 I and Xho I restriction sites in lowercase) under the control of a cytomegalovirus (CMV) promoter. All the constructs also contain a green fluorescence protein (GFP) under the control of a separate CMV promoter. All final virus constructs were purified by ultracentrifugation in CsCl gradient, dialyzed, confirmed by sequencing and titrated in HEK cells.
- CMV cytomegalovirus
- Human umbilical venous endothelial cells were cultured in EGM2 Bullet Kit medium (Lonza, Basel, Switzerland) on dishes coated with type 1 rat tail collagen (VWR, Radnor, Pa.).
- Human umbilical vascular smooth muscle cells (VSMC) and SmGM-2 Bullet Kit medium were purchased from Lonza. The cells in all assays were below passage 6 and cultured at a density that allowed cell division throughout the course of the experiment.
- TaqMan® microRNA Assays (Life Technologies) were used to quantify mature miRNAs.
- cDNA was synthesized by priming with miRNA-specific looped primers, or U18 as endogenous control.
- PCR was performed using 4.5 ng cDNA, 1 ⁇ TaqMan® Universal PCR Master Mix (P/N: 4324018) and TaqMan® MicroRNA assay.
- VSMC and EC were infected with 20 or 30 pfu/cell, respectively.
- Proliferation assay was carried out six days after infection by using the Cell-Proliferation-Reagent kit (Roche, Basel, Switzerland) according to the manufacturer's instruction. The absorbance was measured at 450 nm (with 690 nm reference wavelength) using Infinite® F500 microplate reader (Tecan, Gurnnedorf, Switzerland). Cellular migration was assessed as previously described (1). The formation of network-like structures assay was performed and quantified as previously described and validated (1, 2). Several fields of view were captured per well and experiments were repeated three times by blinded observers.
- Immunoblot analysis was performed as previously described (3). Briefly, samples were resolved by SDS-PAGE and proteins transferred to poly-vinylidene difluoride and visualized by immunoblotting using infrared-labeled anti-rabbit (red) and anti mouse (green) secondary antibodies (1:10,000, LI-COR Biosciences. Lincoln, Nebr.). Band intensities were quantified with the Odyssey Infrared Imaging System (LI-COR Biosciences). Blots were probed with the following antibodies: rabbit anti-GAPDH (Cell signaling Technology®), rabbit anti-GFP (Life Technologies) and mouse anti-p27 (BD Transduction LaboratoriesTM), San Jose, Calif.). Data are presented as arbitrary units after normalization for GAPDH as loading control.
- the animals were housed in a 22° C. room with a 12-hour light/dark cycle. Balloon injury of the right carotid artery was performed in male Sprague Dawley rats (weighing 300 ⁇ 30 g, Harlan, South Easton, Mass.) using a HyperGlideTM ballon catheter (Micro Therapeutics, Inc. Irvine, Calif.), partially modifying a previously described procedure (4). Briefly, the animals were anesthetized by isoflurane (4%) inhalation and maintained by mask ventilation (isoflurane 2%), and the right common, external and internal carotid arteries were exposed and isolated. Through the external carotid, the balloon catheter was introduced in the common carotid and inflated 7 times.
- the common carotid artery was flushed twice with PBS, and a solution of PBS and adenovirus [5 ⁇ 10 9 plaque-forming unit (pfu)/100 ⁇ l] was injected and allowed to incubate in the common carotid in the absence of flow for 20 min.
- the tension of common carotid artery was maintained by placing microvascular clips (Harvard Apparatus, Holliston, Mass.) on the internal and the common carotids (5).
- the adenovirus then was removed, the external carotid was tied and the blood flow was restored through the common and the internal carotid arteries. Following wound closure, the rats were given ad libitum access to food and water. All experiments were performed by blinded investigators.
- Hypercoagulability was assessed measuring plasma levels of D-dimer (6) using a rat immunoassay (USCN Life Science Inc. Houston, Tex.) in accordance to the manufacturer's instructions.
- the rats were euthanized and the carotid arteries were fixed by perfusion at 100 mmHg with 100 ml of PBS, followed by 80 ml of PBS containing 4% paraformaldehyde via a cannula placed in the left ventricle. Both right and left common carotid arteries were then excised, cut in two portions and embedded in optimal cutting temperature (OCT) medium (Sakura Finetek, Tokyo, Japan) for cryosectioning. Subsequently, 10 ⁇ m sections were cut every 20 ⁇ m and submitted in toto for histological evaluation.
- OCT optimal cutting temperature
- Sections were processed for staining with anti- ⁇ -smooth muscle actin ( ⁇ -SMA, Sigma-Aldrich, 1:1000 for 3 h at room temperature), anti VE cadherin (Abeam, Cambridge, Mass., 1:100 overnight at 4° C.) specific for EC (7), anti GFP (Life Technologies, 1:1000 overnight at 4° C.) antibodies.
- Fluorescent-labeled secondary antibodies (1:1000) were incubated at room temperature for 1 hour. Samples were then washed with PBS and mounted with SlowFade® Gold antifade reagent with DAPI (Life Technologies).
- Neointima/media ratios were calculated using a computerized image analysis system (Image J), as previously described (4).
- Endothelium-dependent vasorelaxation was assessed in vessels pre-constricted with phenylephrine (10 ⁇ 5 M) in response to acetylcholine from 10 ⁇ 9 to 10 ⁇ 6 M, freshly prepared on the day of experiment (5, 9). Concentrations are reported as the final molar value in the organ bath. Endothelium-independent vasodilatation was tested after mechanical endothelium removal of the endothelial layer.
- Coronary artery disease is currently a leading cause of death worldwide.
- DES drug-eluting stents
- EC delayed endothelial cell
- VSMC vascular smooth muscle cell
- VSMC proliferation and migration was specifically inhibited, while EC were able to proliferate, migrate and form capillary-like networks.
- Balloon injured rat carotid artery infected with p27-126TS viruses exhibited complete inhibition of restenosis with complete re-endothelialization after two weeks ( FIG. 3B ).
- hypercoagulability assessed by measuring plasma levels of D-dimer in the serum of rats treated with the p27-126TS was similar to the non-injured control ( FIG. 3D ).
- vasodilatative response to acetylcholine of balloon injured carotid arteries treated with p27-126TS adenovirus were comparable to those of the control-noninjured vessel ( FIG. 3E ).
- the data above can lead to a safer therapy than the non-selective DES and can diminish the need for prolonged dual antiplatelet therapy following percutaneous coronary intervention.
- Antithrombotic and/or antiinflammatory genes will be incorporated into the adenovirus expression vectors described in the examples above, or into any other DNA delivery system, as described in the Detailed Description. Such genes will be incorporated into the adenovirus vectors under the control of a second CMV promoter.
- Example antithrombotic and/or antiinflammatory genes include the following:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 61/620,404, filed Apr. 4, 2012 and U.S. Provisional Application No. 61/727,003, filed Nov. 15, 2012, the contents of which are incorporated by reference herein in their entireties.
- This invention was made with government support under Grant No. K99HL109133-01 awarded by the National Institute of Health. The Government has certain rights in the invention.
- This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.
- All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosure of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described herein.
- The high incidence of cardiovascular diseases represents a significant medical problem in the USA and throughout the world, despite remarkable advances over the past few decades. From the 1990's to early 2000's, restenosis after balloon angioplasty and/or stent implantation occurred with an incidence of approximately 50% and 25%, respectively, leading to a significant limitation in its effectiveness.
- A major advance in the treatment of coronary artery disease (CAD) emerged from studies showing that rapamycin was a potent inhibitor of proliferation and migration of VSMCs, and led to the development of rapamycin-coated stents (Cypher) which markedly reduced restenosis and revolutionized the field of percutaneous coronary intervention (PCI).
- Percutaneous coronary intervention (PCI) is one of the most commonly performed interventions that have transformed the practice of revascularization for CAD. However, the major drawback of this procedure is the proliferation and subsequent accumulation of vascular smooth muscle cells (VSMC), leading to restenosis. The advent of drug eluting stents, capable of delivering an inhibitor of cell proliferation in situ has decreased, but not eliminated, the occurrence of restenosis. The drugs that elute from the stent not only inhibit VSMC, but also EC proliferation and migration, increasing the risk of late thrombosis. Thus, there is a need for therapies that would provide VSMC selective anti-proliferative activity without affecting EC.
- The present invention provides for the incorporation of target sequences for a microRNA into the 3′-UTR of a gene, such as, but not limited to, a tumor suppressor gene, that is present in an expression vector. The expression vector is used to specifically over-express the gene in one cell type that either does not express the microRNA, or has very low expression levels of the microRNA, while inhibiting the expression of the gene in another cell type that has higher expression levels of the microRNA.
- In one aspect, the present invention provides a nucleic acid vector comprising a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the gene of interest is the p27 gene. In one embodiment, the microRNA is miR-126. In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the target sequences for a microRNA are identical. In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest.
- In another embodiment, the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector. In another embodiment, the vector is delivered to a cell of interest. In one embodiment, the cell of interest is an endothelial cell.
- In another aspect, the invention provides an expression system comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the gene of interest is the p27 gene. In one embodiment, the microRNA is miR-126. In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the target sequences for a microRNA are identical. In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In another embodiment, the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- In another aspect, the invention provides a cell comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the gene of interest is the p27 gene. In one embodiment, the microRNA is miR-126. In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the target sequences for a microRNA are identical. In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2.
- In one embodiment, the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector. In one embodiment, the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell.
- In one aspect, the invention provides a pharmaceutical composition comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the gene of interest is the p27 gene. In one embodiment, the microRNA is miR-126. In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the target sequences for a microRNA are identical. In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2.
- In one embodiment, the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In another embodiment, the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- In another aspect, the invention provides a method of treating or preventing a cardiovascular disease in a subject in need thereof, the method comprising administering a nucleic acid vector to the subject, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the gene of interest is the p27 gene. In one embodiment, the microRNA is miR-126. In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the target sequences for a microRNA are identical. In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2.
- In one embodiment, the vector comprises a second gene of interest. In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In another embodiment, the nucleic acid vector is a viral vector. In yet another embodiment, the viral vector is an adenoviral vector.
- In one embodiment, the nucleic acid vector is delivered into a cell of the subject. In another embodiment, the cell expresses the microRNA. In one embodiment, the gene of interest is not expressed in the cell. In one embodiment, the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell. In one embodiment, the cardiovascular disease is coronary artery disease.
- These, and other, embodiments of the invention will be better appreciated and understood when considered in conjunction with the following description and the accompanying drawings. It should be understood, however, that the following description, while indicating various embodiments of the invention and numerous specific details thereof, is given by way of illustration and not of limitation. Many substitutions, modifications, additions and/or rearrangements may be made within the scope of the invention without departing from the spirit thereof, and the invention includes all such substitutions, modifications, additions and/or rearrangements.
-
FIGS. 1A-D . Schematic representation of p27-expressing viruses.FIG. 1A . Control CMV virus (CMV)FIG. 1B . p27 expressing adenovirus under the control of CMV promoter (p27).FIG. 1C . p27 expressing adenovirus under the control of CMV promoter, containing four target sequences for mir-126 in their 3′UTR (p27-126TS).FIG. 1D . Representative immunoblots for the indicated proteins from VSMC or HUVEC infected with adenovirus described in A-C at 20 pfu/cell or 50 pfu/cell respectively for 48 hr. -
FIGS. 2A-J . Ad-p27-126TS preserves EC function in vitro.FIG. 2A . Real Time qRT-PCR analysis of miR-126 (FIGS. 2B-C ) Representative immunoblot of three independent experiments quantified by densitometry.FIG. 2D . Proliferation assays of VSMC and EC infected with the indicated Ad. Migration assays of VSMC (FIGS. 2E , F) and EC (FIGS. 2G , H) infected with the indicated Ad; representative pictures at the indicated time points are shown.FIGS. 2I , J. Network formation assay in EC. Orange scale bar indicates 100 μm (magnification 4×). All data shown are means±s.e.m. from at least three experiments performed in quadruplets. Data comparisons were made using one way analysis of variance with Bonferroni post hoc tests; *P<0.01 versus VSMC (FIG. 2A ); *P<0.01 versus Ad-GFP (FIGS. 2C , D, F, H, J). -
FIGS. 3A-E . Effects of Ad-p27-126TS in an in vivo model of arterial injury.FIG. 3A . Representative sections of rat carotid arteries immunostained for smooth muscle cell actin (αSMA) and for the specific EC marker VE-Cadherin (VE-Cad). Nuclei were counterstained with DAPI. No positive staining was observed in the negative control sections. Orange scale bars: 100 μm (magnification 60×, inlays show high magnification images), arrowheads indicate EC beyond the inner autofluorescent elastic laminae.FIG. 3B . Neointima/media ratios and (FIG. 3C ) endothelial coverage were calculated from 5 rats/group.FIG. 3D . Plasma levels of D-dimer in plasma collected before (uninjured) and 2 weeks after the balloon injury using a specific rat immunoassay; n=4 rats/group.FIG. 3E . Vascular reactivity analysis on carotid rings showing the vasodilatative response to acetylcholine (ACh); n=3 rats/group. All the data are means±s.e.m. from at least three experiments performed in triplicate. Data comparison was made using one way (FIGS. 3B-D ) or two-way repeated measures (FIG. 3E ) analysis of variance with Bonferroni post hoc tests; *P<0.01 versus uninjured. -
FIGS. 4A-C . Schematic representation of the used adenoviruses (Ad). A pAdTrack-CMV vector that contains a green fluorescence protein (GFP) under the control of a separate CMV promoter was used to generate three adenoviruses:FIG. 4A . The Ad-GFP contains only the sequence for GFP.FIG. 4B . The Ad-p27 contains the sequences for GFP and p27.FIG. 4C . The Ad-p27-126TS contains GFP and p27 that have four target sequences for miR-126 in its 3′UTR. -
FIGS. 5A-B . Histological assessment of rat carotid arteries 2 weeks after injury and adenoviral infection.FIG. 5A . To overcome the autofluorescence issues typical of the vascular sections, the efficiency of the Ad infection was evaluated by using a primary antibody against GFP, revealed by a Cy3-conjugated secondary antibody. Representative digital images are shown. Orange scale bar represents 100 μm (magnification 60×).FIG. 5B . Representative sections stained with hematoxilyn/eosin (magnification 10×, inlays show the whole arterial section in a 5× magnification; orange scale bar represents 500 μm). - The patent and scientific literature referred to herein establishes knowledge that is available to those skilled in the art. The issued patents, applications, and other publications that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.
- As would be apparent to one of ordinary skill in the art, any method or composition described herein can be implemented with respect to any other method or composition described herein.
- As used herein, the term “p27” refers to the cyclin-dependent kinase inhibitor also known as p27Kip1, which is a member of the kinase inhibitor protein (KIP) family. p27 is a protein encoded by the CDKN1B gene. The nucleic acid sequences of the gene encoding p27, including, but not limited to, the nucleic acid sequence of the open reading frame of the gene, is known in the art. The nucleic acid sequences of the gene encoding human p27, including, but not limited to, the nucleic acid sequence of the open reading frame of the human gene, is known in the art. The amino acid sequences of the p27 polypeptide and protein, including, but not limited to, the amino acid sequences of the human p27 polypeptide and proteins, are known in the art. The GeneBank accession number of the nucleic acid sequence of human p27 is NM—004064. The GeneBank accession number of the amino acid sequence of human p27 is NP—004055. For additional information on p27, see e.g., Nisar P. Malek, Holly Sundberg, Seth McGrew, Keiko Nakayama, Themis R. Kyriakidis & James M. Roberts, 2001, A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase, Nature, 413, 323-327. p27 is also known as KIP1; MEN4; CDKN4, MEN1B and P27KIP1.
- As used herein, the term “miR-126” refers to
microRNA 126. The nucleic acid sequence of miR-126 is known in the art. The nucleic acid sequences of human miR-126 is known in the art. The GeneBank accession number of the nucleic acid sequence of human miR-126 is M10000471. - As used herein, the abbreviation “HUVEC” refers to Human Umbilical Venous Endothelial Cells.
- As used herein, the abbreviation “EC” refers to Endothelial Cells.
- As used herein, the abbreviation “VSMC” refers to Vascular Smooth Muscle Cells.
- As used herein, the abbreviation “SMC” refers to smooth muscle cells.
- The singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.
- The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one.” and “one or more than one.”
- The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20%.
- Treatment of Coronary Artery Disease
- Cardiovascular disease accounts for nearly one third of deaths globally, and Coronary Artery Disease (CAD) remains the number one cause of death in the United States (Heron M, Hoyert D L, Murphy S L, Xu J, Kochanek K D, Tejada-Vera B: Deaths: final data for 2006. Natl Vital Stat Rep 57(14), 1-134 (2009)).
- The introduction of the Drug-Eluting Stent (DES) has revolutionized the field of angioplasty, by significantly reducing rates of restenosis when compared to bare-metal stents (BES) (Marks A R: Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 349(14), 1307-1309 (2003). The anti-restenotic action of the drug (Sirolimus or rapamycin) lies at least in part, on its ability to up-regulate levels of p27, a widely expressed protein that inhibits cyclin-dependent kinases (cdks) complexes in G1 and S phases (Marx S O, Totary-Jain H, Marks A R: Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Intenr 4(1), 104-111 (2011). Despite the significant improvement, drug-eluting stents (DES) hike the risk of late stent thrombosis by about 0.2% over bare-metal stents and is associated with long-term myocardial infarction and death rates (Garg S, Serruys P W: Coronary stents: looking forward. J Am Coll Cardiol 56(10 Suppl). S43-78 (2010): Wijns W: Late stent thrombosis after drug-eluting stent: seeing is understanding. Circulation 120(5), 364-365 (2009)). Delayed endothelial coverage after DES implantation is thought to prolong the window of vulnerability to stent thrombosis, which requires a prolonged dual anti-platelet therapy (Van Den Heuvel M, Sorop O, Van Beusekom H M, Van Der Giessen W J: Endothelial dysfunction after drug eluting stent implantation. Minerva Cardioangiol 57(5), 629-643 (2009)).
- The current generation of DES that elute non selective drugs from their surfaces to reduce smooth muscle cell growth also inhibit endothelialisation (Finn A V, Nakazawa G, Joner M el al.: Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27(7), 1500-1510 (2007); Joner M, Finn A V, Farb A et al.: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1), 193-202 (2006)).
- Newer stents and coronary devices are currently undergoing pre-clinical and clinical trials including DES with biodegradable polymers, polymer free DES, new coated stents, completely biodegradable stents, bifurcation stents and drug-eluting balloons. However, these new approaches continue to utilize non-selective antiproliferative drugs that inhibit both vascular smooth muscle cells (VSMC) and vascular endothelial cell (EC) proliferation, adversely affecting critical endothelial cell functions such as maintaining vascular tone, providing a permeable barrier, modulating adhesion, inflammation and thrombosis. Therefore, it is of paramount importance to develop therapeutic strategies that can selectively inhibit VSMC and other infiltrated cells without affecting EC functions. The present invention addresses this need.
- The present invention provides for the incorporation of target sequences for a microRNA into the 3′-UTR of a gene, such as, but not limited to, a tumor suppressor gene, that is present in an expression vector. The expression vector is used to specifically over-express the gene in one cell type that either does not express the microRNA, or has very low expression levels of the microRNA, while inhibiting the expression of the gene in another cell type that has higher expression levels of the microRNA.
- In one embodiment, the present invention provides for the incorporation of target sequences for the VEC-specific miRNA, miR-126, into the 3′-UTR of p27 in a p27-expressing vector, to specifically over-express p27 in vascular smooth muscle cells (VSMC), without affecting endothelial cells (EC) that express mir-126 at higher levels than VSMC. This strategy will result in the specific inhibition of VSMC proliferation, migration and neointimal formation, without affecting endothelial cells, because p27-expressing vectors will be targeted for degradation in endothelial cells.
- The invention can be used, for example, in conjunction with BMS implantation to provide the benefits of a DES without the concern of DES post-operative complications. The invention can be used, for example, for the inhibition of VSMC proliferation in altherosclerosis and arterial injury, as well as vascular access failure in hemodialysis patients.
- MicroRNAs
- A variety of nucleic acid species are capable of modifying gene expression. These include antisense RNA, siRNA, microRNA, RNA and DNA aptamers, and decoy RNAs. Each of these nucleic acid species can inhibit target nucleic acid activity, including gene expression.
- MicroRNAs (miRNAs or miRs) are a class of short (18-25 nt) non-coding RNAs (ncRNAs) that exist in a variety of organisms, including mammals, and are conserved in evolution. miRNAs are processed from hairpin precursors of 70 nt (pre-miRNA) which are derived from primary transcripts (pri-miRNA) through sequential cleavage by the RNAse III enzymes drosha and dicer. miRNAs can be encoded in intergenic regions, hosted within introns of pre-mRNAs or within ncRNA genes. Many miRNAs also tend to be clustered and transcribed as polycistrons and often have similar spatial temporal expression patterns. miRNAs have been found to have roles in a variety of biological processes including developmental timing, differentiation, apoptosis, cell proliferation, organ development, and metabolism.
- At least 222 separate miRNA genes have been identified in the human genome. For example, 2 miRNA genes (miR15a and miR16a) have been localized to a homozygously deleted region on chromosome 13 that is correlated with chronic lymphocytic leukemia (Calin et al. (2002), Proc. Natl. Acad. Sci. USA 99:15524-29). However, the distribution of miRNA genes throughout the genome, and the relationship of the miRNA genes to diverse chromosomal features, has not been systematically studied. A further review of miRNAs is provided in U.S. Pat. No. 7,232,806, U.S. Patent Application Publication No. 2006/0105360, and in the references: Landgraf et al., 2007, Cell 129: 1401-1414; Mendell, J T, 2005 Cell Cycle 4(9):1179-84; Shivdasani R A, 2006 Blood 108(12):3646-53; Hwang and Mendell, 2006 Br J Cancer 94(6):776-80; Hammond S M, 2006: Curr Opin Genet Dev. 16(1):4-9; Osada and Takahashi, 2007 Carcinogenesis 28(1):2-12; and Zhang et al., 2007 Dev Biol. 302(1):1-12, all of which are hereby incorporated by reference in their entirety.
- MicroRNAs can inhibit target nucleic acid activity, including gene expression. For example, miRNAs can function via base paring with complementary nucleic acid sequences within mRNA molecules. The pairing of miRNAs with complementary mRNA molecules usually results in gene silencing via translational repression or target degradation. Animal miRNAs can exhibit only partial complementarity to their mRNA targets. A seed region of about 6-8 nucleotides in length at the 5′ end of an miRNA is thought to be an important determinant of target specificity. A given miRNA can have multiple different mRNA targets and a given target can be targeted by multiple miRNAs. For additional information on miRNAs, see also Ishida el al., 2013, miRNA-Based Therapeutic Strategies, Curr Anesthesiol Rep., 1(1):63-70, which is incorporated herein by reference in its entirety.
- Nucleic Acid Vectors and Expression Systems
- In one aspect, the present invention provides a nucleic acid vector comprising a gene of interest, and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- In one embodiment, the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- In one embodiment, the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical. The nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In one embodiment, the second gene of interest is a human gene. In another embodiment, the second gene of interest is a non-human gene. In one embodiment, the second gene of interest is p53. In other embodiments, the second gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4. In one embodiment, the second gene of interest is an antithrombotic gene. In another embodiment, the second gene of interest is an anti-inflammatory gene. In another embodiment, the second gene of interest is ENTPD1, TFPI or PTGIS.
- In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the vector comprises one target sequence. In another embodiment, the vector comprises two target sequences. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the nucleic acid vector is a viral vector. In one embodiment, the viral vector is an adenoviral vector. In another embodiment, the viral vector is a lentiviral vector. In one embodiment, the vector is a retroviral vector. In another embodiment, is an oncoviral vector. Examples of adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12). In a further embodiment, the vector is an adeno-associated vector. Examples of adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2). Examples of lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2. Examples of retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV). Examples of oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- In another embodiment, the vector is delivered to a cell of interest. Delivery can be conducted by any method known to one of skill in the art, including, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- In one embodiment, the cell of interest is an endothelial cell. In another embodiment, the cell of interest is a vascular smooth muscle cell. In further embodiments, the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell. Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- In another embodiment, the cell of interest is a cancer cell. The cancer can be, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- In another aspect, the invention provides an expression system comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- In one embodiment, the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- In one embodiment, the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical. The nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In one embodiment, the second gene of interest is a human gene. In another embodiment, the second gene of interest is a non-human gene. In one embodiment, the second gene of interest is p53. In other embodiments, the second gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4. In one embodiment, the second gene of interest is an antithrombotic gene. In another embodiment, the second gene of interest is an anti-inflammatory gene. In another embodiment, the second gene of interest is ENTPD1, TFPI or PTGIS.
- In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the vector comprises one target sequence. In another embodiment, the vector comprises two target sequences. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the nucleic acid vector is a viral vector. In one embodiment, the viral vector is an adenoviral vector. In another embodiment, the viral vector is a lentiviral vector. In one embodiment, the vector is a retroviral vector. In another embodiment, is an oncoviral vector. Examples of adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12). In a further embodiment, the vector is an adeno-associated vector. Examples of adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2). Examples of lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2. Examples of retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV). Examples of oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- In another aspect, the invention provides a cell comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- In one embodiment, the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- In one embodiment, the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical. The nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In one embodiment, the second gene of interest is a human gene. In another embodiment, the second gene of interest is a non-human gene. In one embodiment, the second gene of interest is p53. In other embodiments, the second gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4. In one embodiment, the second gene of interest is an antithrombotic gene. In another embodiment, the second gene of interest is an anti-inflammatory gene. In another embodiment, the second gene of interest is ENTPD1, TFPI or PTGIS.
- In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the vector comprises one target sequence. In another embodiment, the vector comprises two target sequences. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the nucleic acid vector is a viral vector. In one embodiment, the viral vector is an adenoviral vector. In another embodiment, the viral vector is a lentiviral vector. In one embodiment, the vector is a retroviral vector. In another embodiment, is an oncoviral vector. Examples of adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12). In a further embodiment, the vector is an adeno-associated vector. Examples of adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2). Examples of lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2. Examples of retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV). Examples of oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- In another embodiment, the cell expresses the microRNA. In another embodiment, the cell does not express the microRNA.
- In one embodiment, the gene of interest is not expressed in the cell. In another embodiment, the gene of interest is expressed in the cell. In one embodiment, the second gene of interest is not expressed in the cell. In another embodiment, the second gene of interest is expressed in the cell.
- In one embodiment, the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell. In further embodiments, the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell. Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- In another embodiment, the cell is a cancer cell. In one embodiment, the cancer is, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- In other embodiments, the nucleic acid vector is delivered into the cell by any method known to one of skill in the art, such as, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- The present invention utilizes conventional molecular biology, microbiology, and recombinant DNA techniques available to one of ordinary skill in the art. Such techniques are well known to the skilled worker and are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, “Molecular Cloning: A Laboratory Manual” (1982): “DNA Cloning: A Practical Approach,” Volumes I and II (D. N. Glover, ed., 1985); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Nucleic Acid Hybridization” (B. D. Hames & S. J. Higgins, eds., 1985); “Transcription and Translation” (B. D. Hames & S. J. Higgins, eds., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1986); “Immobilized Cells and Enzymes” (IRL Press, 1986): B. Perbal, “A Practical Guide to Molecular Cloning” (1984), and Sambrook, et al., “Molecular Cloning: a Laboratory Manual” (1989).
- Nucleic acid sequences of various microRNAs, and nucleic acid sequences of various target sequences for microRNAs, are available in the art.
- The nucleic acid sequence of miR-126 is depicted in SEQ ID NO: 1.
- SEQ ID NO: 1 is a sequence of human miR-126 (residues 1-22)
-
UCGUACCGUGAGUAAUAAUGCG - The nucleic acid sequence of a target sequence of miR-126 is depicted in SEQ ID NO: 2.
- SEQ ID NO: 2 is a nucleic acid target sequence of human miR-126 (residues 1-22)
-
CGCATTATTACTCACGGTACGA
One of skill in the art can determine the complementary sequence of a nucleic acid target sequence of a microRNA, such as, but not limited to, SEQ ID NO. 2. - One skilled in the art can obtain a protein in several ways, which include, but are not limited to, isolating the protein via biochemical means or expressing a nucleotide sequence encoding the protein of interest by genetic engineering methods.
- A protein is encoded by a nucleic acid (including, for example, genomic DNA, complementary DNA (cDNA), synthetic DNA, as well as any form of corresponding RNA). For example, it can be encoded by a recombinant nucleic acid of a gene. The proteins of the invention can be obtained from various sources and can be produced according to various techniques known in the art. For example, a nucleic acid that encodes a protein can be obtained by screening DNA libraries, or by amplification from a natural source. A protein can be a fragment or portion thereof. The nucleic acids encoding a protein can be produced via recombinant DNA technology and such recombinant nucleic acids can be prepared by conventional techniques, including chemical synthesis, genetic engineering, enzymatic techniques, or a combination thereof. For example, a p27 protein is the polypeptide encoded by the nucleic acid having the nucleotide sequence shown in SEQ ID NO: 4. An example of an p27 polypeptide has the amino acid sequence shown in SEQ ID NO: 3.
- The polypeptide sequence of human p27 is depicted in SEQ ID NO: 3. The nucleotide sequence of human p27 is shown in SEQ ID NO: 4. Sequence information related to p27 is accessible in public databases by GenBank Accession numbers NM—004064 (for nucleic acid) and NP—004055 (for protein).
- SEQ ID NO: 3 is the human wild type amino acid sequence corresponding to p27 (residues 1-198)
-
msnvrvsngs pslermdarq aehpkpsacr nlfgpvdhee ltrdlekhcr dmeeasqrkw nfdfqnhkpl egkyewqeve kgslpefyyr pprppkgack vpaqesqdvs gsrpaaplig apansedthl vdpktdpsds qtglaeqcag irkrpatdds stqnkranrt eenvsdgspn agsveqtpkk pglrrrqt - SEQ ID NO: 4 is the human wild type nucleic acid sequence corresponding to p27 (residues 1-2413)
-
1 cttcttcgtc agcctccctt ccaccgccat attgggccac taaaaaaagg gggctcgtct 61 tttcggggtg tttttctccc cctcccctgt ccccgcttgc tcacggctct gcgactccga 121 cgccggcaag gtttggagag cggctgggtt cgcgggaccc gcgggcttgc acccgcccag 181 actcggacgg gctttgccac cctctccgct tgcctggtcc cctctcctct ccgccctccc 241 gctcgccagt ccatttgatc agcggagact cggcggccgg gccggggctt ccccgcagcc 301 cctgcgcgct cctagagctc gggccgtggc tcgtcggggt ctgtgtcttt tggctccgag 361 ggcagtcgct gggcttccga gaggggttcg ggctgcgtag gggcgctttg ttttgttcgg 421 ttttgttttt ttgagagtgc gagagaggcg gtcgtgcaga cccgggagaa agatgtcaaa 481 cgtgcgagtg tctaacggga gccctagcct ggagcggatg gacgccaggc aggcggagca 541 ccccaagccc tcggcctgca ggaacctctt cggcccggtg gaccacgaag agttaacccg 601 ggacttggag aagcactgca gagacatgga agaggcgagc cagcgcaagt ggaatttcga 661 ttttcagaat cacaaacccc tagagggcaa gtacgagtgg caagaggtgg agaagggcag 721 cttgcccgag ttctactaca gacccccgcg gccccccaaa ggtgcctgca aggtgccggc 781 gcaggagagc caggatgtca gcgggagccg cccggcggcg cctttaattg gggctccggc 841 taactctgag gacacgcatt tggtggaccc aaagactgat ccgtcggaca gccagacggg 901 gttagcggag caatgcgcag gaataaggaa gcgacctgca accgacgatt cttctactca 961 aaacaaaaga gccaacagaa cagaagaaaa tgtttcagac ggttccccaa atgccggttc 1021 tgtggagcag acgcccaaga agcctggcct cagaagacgt caaacgtaaa cagctcgaat 1081 taagaatatg tttccttgtt tatcagatac atcactgctt gatgaagcaa ggaagatata 1141 catgaaaatt ttaaaaatac atatcgctga cttcatggaa tggacatcct gtataagcac 1201 tgaaaaacaa caacacaata acactaaaat tttaggcact cttaaatgat ctgcctctaa 1261 aagcgttgga tgtagcatta tgcaattagg tttttcctta tttgcttcat tgtactacct 1321 gtgtatatag tttttacctt ttatgtagca cataaacttt ggggaaggga gggcagggtg 1381 gggctgagga actgacgtgg agcggggtat gaagagcttg ctttgattta cagcaagtag 1441 ataaatattt gacttgcatg aagagaagca attttgggga agggtttgaa ttgttttctt 1501 taaagatgta atgtcccttt cagagacagc tgatacttca tttaaaaaaa tcacaaaaat 1561 ttgaacactg gctaaagata attgctattt atttttacaa gaagtttatt ctcatttggg 1621 agatctggtg atctcccaagactatctaaag tttgttagat agctgcatgt ggctttttta 1681 aaaaagcaac agaaacctat cctcactgcc ctccccagtc tctcttaaag ttggaattta 1741 ccagttaatt actcagcaga atggtgatca ctccaggtag tttggggcaa aaatccgagg 1801 tgcttgggag ttttgaatgt taagaattga ccatctgctt ttattaaatt tgttgacaaa 1861 attttctcat tttcttttca cttcgggctg tgtaaacaca gtcaaaataa ttctaaatcc 1921 ctcgatattt ttaaagatct gtaagtaact tcacattaaa aaatgaaata ttttttaatt 1981 taaagcttac tctgtccatt tatccacagg aaagtgttat ttttcaagga aggttcagtg 2041 agagaaaagc acacttgtag gataagtgaa atggatacta catctttaaa cagtatttca 2101 ttgcctgtgt atggaaaaac catttgaagt gtacctgtgt acataactct gtaaaaacac 2161 tgaaaaatta tactaactta tttatgttaa aagatttttt ttaatctaga caatatacaa 2221 gccaaagtgg catgttttgt gcatttgtaa atgctgtgtt gggtagaata ggttttcccc 2281 tcttttgtta aataatatgg ctatgcttaa aaggttgcat actgagccaa gtataatttt 2341 ttgtaatgtg tgaaaaagat gccaattatt gttacacatt aagtaatcaa taaagaaaac 2401 ttccatagct att - p27 is a protein encoded by the CDKN1B gene. p27 is a cyclin-dependent kinase inhibitor, and is also known as p27Kip1. It is a member of the kinase inhibitor protein (KIP) family. For additional information on p27, see e.g., Nisar P. Malek, Holly Sundberg, Seth McGrew, Keiko Nakayama. Themis R. Kyriakidis & James M. Roberts, 2001, A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase, Nature, 413, 323-327.
- Protein Variants
- Protein variants can include amino acid sequence modifications. For example, amino acid sequence modifications fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions can include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture.
- Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions can be single residues, but can occur at a number of different locations at once. In one non-limiting embodiment, insertions can be on the order of about from 1 to about 10 amino acid residues, while deletions can range from about 1 to about 30 residues. Deletions or insertions can be made in adjacent pairs (for example, a deletion of about 2 residues or insertion of about 2 residues). Substitutions, deletions, insertions, or any combination thereof can be combined to arrive at a final construct. The mutations cannot place the sequence out of reading frame and should not create complementary regions that can produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place.
- Substantial changes in function or immunological identity are made by selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions that can produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue: (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.
- Minor variations in the amino acid sequences of proteins are provided by the present invention. The variations in the amino acid sequence can be when the sequence maintains at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% identity to SEQ ID NO: 3, or any other amino acid sequence of interest. For example, conservative amino acid replacements can be utilized. Conservative replacements are those that take place within a family of amino acids that are related in their side chains, wherein the interchangeability of residues have similar side chains.
- Genetically encoded amino acids are generally divided into families: (1) acidic amino acids are aspartate, glutamate: (2) basic amino acids are lysine, arginine, histidine; (3) non-polar amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and (4) uncharged polar amino acids are glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. The hydrophilic amino acids include arginine, asparagine, aspartate, glutamine, glutamate, histidine, lysine, serine, and threonine. The hydrophobic amino acids include alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine. Other families of amino acids include (i) a group of amino acids having aliphatic-hydroxyl side chains, such as serine and threonine; (ii) a group of amino acids having amide-containing side chains, such as asparagine and glutamine; (iii) a group of amino acids having aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; (iv) a group of amino acids having aromatic side chains, such as phenylalanine, tyrosine, and tryptophan; and (v) a group of amino acids having sulfur-containing side chains, such as cysteine and methionine. Useful conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine valine, glutamic-aspartic, and asparagine-glutamine.
- For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr. Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also can be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.
- Bacterial and Yeast Expression Systems
- In bacterial systems, a number of expression vectors can be selected. For example, when a large quantity of a protein encoded by a gene is needed for the induction of antibodies, vectors which direct high level expression of proteins that are readily purified can be used. Non-limiting examples of such vectors include multifunctional E. coli cloning and expression vectors such as BLUESCRIPT (Stratagene). pIN vectors or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptide molecules as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
- Plant and Insect Expression Systems
- If plant expression vectors are used, the expression of sequences encoding a protein can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters, can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.
- An insect system also can be used to express proteins. For example, in one such system Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. Sequences encoding a polypeptide can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of nucleic acid sequences, such as a sequence corresponding to a gene of interest, will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect S. frugiperda cells or Trichoplusia larvae in which the protein or a variant thereof can be expressed.
- Mammalian Expression Systems
- An expression vector can include a nucleotide sequence that encodes a polypeptide linked to at least one regulatory sequence in a manner allowing expression of the nucleotide sequence in a host cell. A number of viral-based expression systems can be used to express a protein or a variant thereof in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding a protein can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion into a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which expresses a protein in infected host cells. Transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can also be used to increase expression in mammalian host cells.
- Regulatory sequences are well known in the art, and can be selected to direct the expression of a protein or polypeptide of interest in an appropriate host cell as described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Non-limiting examples of regulatory sequences include: polyadenylation signals, promoters (such as CMV, ASV, SV40, or other viral promoters such as those derived from bovine papilloma, polyoma, and Adenovirus 2 viruses (Fiers, et al., 1973, Nature 273:113; Hager G L, et al., Curr Opin Genet Dev, 2002, 12(2):137-41) enhancers, and other expression control elements.
- Enhancer regions, which are those sequences found upstream or downstream of the promoter region in non-coding DNA regions, are also known in the art to be important in optimizing expression. If needed, origins of replication from viral sources can be employed, such as if a prokaryotic host is utilized for introduction of plasmid DNA. However, in eukaryotic organisms, chromosome integration is a common mechanism for DNA replication.
- Suitable promoters for expressing RNA from a plasmid include, e.g., the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art. Recombinant plasmids can comprise inducible or regulatable promoters for expression of the RNA in cells (such as, but not limited to, vascular smooth muscle cells or endothelial cells). For example, a nucleic acid encoding a gene, such as, but not limited to, a p27 gene, and one or more target sequences for a microRNA, such as, but not limited to, miR-126 (comprising one or more sequences of SEQ ID NO: 2) can be placed under the control of the CMV intermediate-early promoter, whereby the nucleic acid sequences encoding the p27 gene are located 3′ of the promoter, so that the promoter can initiate transcription of the miRNA gene product coding sequences.
- A gene that encodes a selectable marker (for example, resistance to antibiotics or drugs, such as ampicillin, neomycin, G418, and hygromycin) can be introduced into host cells along with the gene of interest in order to identify and select clones that stably express a gene encoding a protein of interest. The gene encoding a selectable marker can be introduced into a host cell on the same plasmid as the gene of interest or can be introduced on a separate plasmid. Cells containing the gene of interest can be identified by drug selection wherein cells that have incorporated the selectable marker gene will survive in the presence of the drug. Cells that have not incorporated the gene for the selectable marker die. Surviving cells can then be screened for the production of the desired protein molecule.
- For stable transfection of mammalian cells, a small fraction of cells can integrate introduced DNA into their genomes. The expression vector and transfection method utilized can be factors that contribute to a successful integration event. For stable amplification and expression of a desired protein, a vector containing DNA encoding a protein of interest is stably integrated into the genome of eukaryotic cells (for example mammalian cells, such as, but not limited to, vascular smooth muscle cells or endothelial cells), resulting in the stable expression of transfected genes. An exogenous nucleic acid sequence can be introduced into a cell (such as a mammalian cell, either a primary or secondary cell) by homologous recombination as disclosed in U.S. Pat. No. 5,641,670, the contents of which are herein incorporated by reference.
- Nucleic acid vectors, such as plasmids, suitable for expressing genes of interest and target sequences for microRNAs, methods for inserting nucleic acid sequences into the plasmid to express the gene of interest, and methods of delivering the recombinant vectors to cells of interest are well-established and practiced in the art. See, for example, Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat. Biotechnol, 20:446-448; Brummelkamp et al. (2002). Science 296:550-553; Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al. (2002), Genes Dev. 16:948-958; Lee et al. (2002), Nat. Biotechnol. 20:500-505; and Paul et al. (2002), Nat. Biotechnol. 20:505-508, the entire disclosures of which are herein incorporated by reference.
- Genes of interest and target sequences for microRNAs can also be expressed from recombinant viral vectors. The RNA expressed from the recombinant viral vectors can either be isolated from cultured cell expression systems by standard techniques, or can be expressed directly in mammalian cells (for example, vascular smooth muscle cells or endothelial cells). For example, the recombinant viral vectors can comprise sequences that encode the gene of interest and any suitable promoter for expressing the RNA sequences. Vectors can also comprise inducible or regulatable promoters for expression of the gene of interest in cells, such as mammalian cells. As discussed previously, non-limiting examples of suitable promoters include the U6 or H1 RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is practiced by those of ordinary skill in the art.
- Any viral vector that can harbor the nucleotide sequences for the gene of interest and the one or more target sequences for a microRNA of the invention can be used. Non-limiting examples of such vectors include: vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g., lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of the viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. For example, AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes. An AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector. Techniques for constructing AAV vectors which express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz J. E. et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.
- Recombinant viral vectors suitable for expressing the gene of interest and the one or more target sequences for a microRNA of the invention, methods for inserting nucleic acid sequences for expressing genes of interest in the vector, methods of delivering the viral vector to cells of interest, and recovery of the expressed nucleic acid molecules and proteins are within the skill in the art. See, for example, Dornburg (1995), Gene Therap. 2:301-310; Eglitis (1988), Biotechniques 6:608-614; Miller (1990), Hum. Gene Therap. 1:5-14; and Anderson (1998), Nature 392:25-30, the entire disclosures of which are herein incorporated by reference. Useful viral vectors can be those derived from AV and AAV. A suitable AV vector for expressing a nucleic acid molecule of the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia et al. (2002), Nat. Biotech. 20:1006-1010, the entire disclosure of which is herein incorporated by reference. Methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski et al. (1987), J. Virol. 61:3096-3101; Fisher et al. (1996). J. Virol. 70:520-532; Samulski et al. (1989), J. Virol. 63:3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788: and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.
- A eukaryotic expression vector can be used to transfect cells in order to produce proteins encoded by nucleotide sequences of the vector. Mammalian cells (such as, but not limited to, vascular smooth muscle cells or endothelial cells) can contain an expression vector (for example, one that contains a gene encoding a p27 protein or polypeptide) via introducing the expression vector into an appropriate host cell via methods known in the art.
- A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed polypeptide encoded by a gene, such as a p27 gene, in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC: 10801 University Boulevard, Manassas, Va. 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.
- An exogenous nucleic acid can be introduced into a cell via a variety of techniques known in the art, such as lipofection, microinjection, calcium phosphate or calcium chloride precipitation. DEAE-dextran-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest (such as cells of the end bulb of a hair follicle, for example dermal papilla cells or dermal sheath cells). Other transfection methods also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- Cells that will be genetically engineered can be primary and secondary cells obtained from various tissues, and include cell types which can be maintained and propagated in culture. Vertebrate tissue can be obtained by methods known to one skilled in the art, such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. A mixture of primary cells can be obtained from the tissue, using methods readily practiced in the art, such as explanting or enzymatic digestion (for examples using enzymes such as pronase, trypsin, collagenase, elastase dispase, and chymotrypsin). Biopsy methods have also been described in United States Patent Application Publication 2004/0057937 and PCT application publication WO 2001/32840, and are hereby incorporated by reference.
- Primary cells can be acquired from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells can also be obtained from a donor, other than the recipient, of the same species. The cells can also be obtained from another species (for example, rabbit, cat, mouse, rat, sheep, goat, dog, horse, cow, bird, or pig). Primary cells can also include cells from an isolated vertebrate tissue source grown attached to a tissue culture substrate (for example, flask or dish) or grown in a suspension; cells present in an explant derived from tissue; both of the aforementioned cell types plated for the first time; and cell culture suspensions derived from these plated cells. Secondary cells can be plated primary cells that are removed from the culture substrate and replated, or passaged, in addition to cells from the subsequent passages. Secondary cells can be passaged one or more times. These primary or secondary cells can contain expression vectors having a gene that encodes a protein of interest (for example, a p27 protein or polypeptide).
- Delivery of nucleic acids into viable cells can be effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., lentivirus, adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). Non-limiting techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, and the calcium phosphate precipitation method (see, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp. 25-20 (1998)). Introduction of a nucleic acid or a gene encoding a polypeptide of the invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured ex vivo in the presence of therapeutic compositions of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
- Nucleic acids can be inserted into vectors and used as gene therapy vectors. A number of viruses have been used as gene transfer vectors, including papovaviruses, e.g., SV40 (Madzak et al., (1992) J Gen Virol. 73(Pt 6):1533-6), adenovirus (Berkner (1992) Curr Top Microbiol Immunol. 158:39-66; Berkner (1988) Biotechniques, 6(7):616-29; Gorziglia and Kapikian (1992) J Virol. 66(7):4407-12; Quantin et al., (1992) Proc Natl Acad Sci USA. 89(7):2581-4; Rosenfeld et al., (1992) Cell. 68(1):143-55; Wilkinson et al., (1992) Nucleic Acids Res. 20(9):2233-9; Stratford-Perricaudet et al., (1990) Hum Gene Ther. 1(3):241-56), vaccinia virus (Moss (1992) Curr Opin Biotechnol. 3(5):518-22), adeno-associated virus (Muzyczka, (1992) Curr Top Microbiol Immunol. 158:97-129; Ohi et al., (1990) Gene. 89(2):279-82), herpesviruses including HSV and EBV (Margolskee (1992) Curr Top Microbhiol Immunol. 158:67-95; Johnson et al., (1992) Brain Res Mol Brain Res. 12(1-3):95-102: Fink et al., (1992) Hum Gene Ther. 3(1):11-9: Breakefield and Geller (1987) Mol Neurobiol. 1(4):339-71; Freese et al., (1990) Biochem Pharmacol. 40(10):2189-99), and retroviruses of avian (Bandyopadhyay and Temin (1984) Mol Cell Biol. 4(4):749-54; Petropoulos et al., (1992) J Virol. 66(6):3391-7), murine (Miller et al. (1992) Mol Cell Biol. 12(7):3262-72; Miller et al., (1985) J Virol. 55(3):521-6; Sorge et al., (1984) Mol Cell Biol. 4(9):1730-7; Mann and Baltimore (1985) J Virol. 54(2):401-7: Miller et al., (1988) J Virol. 62(11):4337-45), and human origin (Shimada et al., (1991) J Clin Invest. 88(3):1043-7; Helseth et al., (1990) J Virol. 64(12):6314-8; Page et al., (1990) J Virol. 64(11):5270-6; Buchschacher and Panganiban (1992) J Virol. 66(5):2731-9).
- Non-limiting examples of in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors (see U.S. Pat. No. 5,252,479, which is incorporated by reference in its entirety) and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11:205-210 (1993), incorporated entirely by reference). For example, naked DNA vaccines are generally known in the art; see Brower, Nature Biotechnology, 16:1304-1305 (1998), which is incorporated by reference in its entirety. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
- For reviews of gene therapy protocols and methods see Anderson et al., Science 256:808-813 (1992); U.S. Pat. Nos. 5,252,479, 5,747,469, 6,017,524, 6,143,290, 6,410,010 6,511,847; 8,398,968; and 8,404,653 which are all hereby incorporated by reference in their entireties. For an example of gene therapy treatment in humans see Porter et al., NEJM 2011 365:725-733 and Kalos et al. Sci. Transl. Med. 2011. 201 3(95):95. For additional reviews of gene therapy technology, see Friedmann. Science, 244:1275-1281 (1989); Verma, Scientific American: 68-84 (1990); Miller, Nature, 357: 455-460 (1992); Kikuchi et al., J Dermatol Sci. 2008 May; 50(2):87-98; Isaka et al., Expert Opin Drug Deliv. 2007 September; 4(5):561-71; Jager et al., Curr Gene Ther. 2007 August; 7(4):272-83; Waehler et al., Nat Rev Genet. 2007 August; 8(8):573-87; Jensen et al., Ann Med. 2007:39(2):108-15; Herweijer et al., Gene Ther. 2007 January; 14(2):99-107; Eliyahu et al., Molecules, 2005 Jan. 31; 10(1):34-64; and Altaras et al., Adv Biochem Eng Biotechnol. 2005; 99:193-260, all of which are hereby incorporated by reference in their entireties.
- Various culturing parameters can be used with respect to the host cell being cultured. Appropriate culture conditions for mammalian cells are well known in the art (Cleveland W L, et al., J Immunol Methods, 1983, 56(2): 221-234) or can be determined by the skilled artisan (see, for example, Animal Cell Culture: A Practical Approach 2nd Ed., Rickwood, D. and Hames, B. D., eds. (Oxford University Press: New York, 1992)). Cell culturing conditions can vary according to the type of host cell selected. Commercially available medium can be utilized. Non-limiting examples of medium include, for example, Minimal Essential Medium (MEM, Sigma, St. Louis, Mo.): Dulbecco's Modified Eagles Medium (DMEM, Sigma); Ham's F10 Medium (Sigma); HyClone cell culture medium (HyClone, Logan, Utah); RPMI-1640 Medium (Sigma); and chemically-defined (CD) media, which are formulated for various cell types, e.g., CD-CHO Medium (Invitrogen, Carlsbad, Calif.).
- The cell culture media can be supplemented as necessary with supplementary components or ingredients, including optional components, in appropriate concentrations or amounts, as necessary or desired. Cell culture medium solutions provide at least one component from one or more of the following categories: (1) an energy source, usually in the form of a carbohydrate such as glucose; (2) all essential amino acids, and usually the basic set of twenty amino acids plus cysteine; (3) vitamins and/or other organic compounds required at low concentrations; (4) free fatty acids or lipids, for example linoleic acid; and (5) trace elements, where trace elements are defined as inorganic compounds or naturally occurring elements that can be required at very low concentrations, usually in the micromolar range.
- The medium also can be supplemented electively with one or more components from any of the following categories: (1) salts, for example, magnesium, calcium, and phosphate: (2) hormones and other growth factors such as, serum, insulin, transferrin, and epidermal growth factor: (3) protein and tissue hydrolysates, for example peptone or peptone mixtures which can be obtained from purified gelatin, plant material, or animal byproducts; (4) nucleosides and bases such as, adenosine, thymidine, and hypoxanthine; (5) buffers, such as HEPES: (6) antibiotics, such as gentamycin or ampicillin; (7) cell protective agents, for example pluronic polyol; and (8) galactose. In one embodiment, soluble factors can be added to the culturing medium.
- The mammalian cell culture that can be used with the present invention is prepared in a medium suitable for the type of cell being cultured. In one embodiment, the cell culture medium can be any one of those previously discussed (for example, MEM) that is supplemented with serum from a mammalian source (for example, fetal bovine serum (FBS)). In another embodiment, the medium can be a conditioned medium to sustain the growth of mammalian cells. In other embodiments of the invention, cells are grown in a suspension culture (for example, a three-dimensional culture such as a hanging drop culture) in the presence of an effective amount of enzyme, wherein the enzyme substrate is an extracellular matrix molecule in the suspension culture. For example, the enzyme can be a hyaluronidase.
- A suspension culture is a type of culture wherein cells, or aggregates of cells multiply while suspended in liquid medium. A suspension culture comprising mammalian cells can be used for the maintenance of cell types that do not adhere or to enable cells to manifest specific cellular characteristics that are not seen in the adherent form. Some types of suspension cultures can include three-dimensional cultures or a hanging drop culture. A hanging-drop culture is a culture in which the material to be cultivated is inoculated into a drop of fluid attached to a flat surface (such as a coverglass, glass slide, Petri dish, flask, and the like), and can be inverted over a hollow surface. Cells in a hanging drop can aggregate toward the hanging center of a drop as a result of gravity. However, according to the methods of the invention, cells cultured in the presence of a protein that degrades the extracellular matrix (such as collagenase, chondroitinase, hyaluronidase, and the like) will become more compact and aggregated within the hanging drop culture, for degradation of the ECM will allow cells to become closer in proximity to one another since less of the ECM will be present. See also International PCT Publication No. WO2007/100870, which is incorporated by reference.
- Three-dimensional cultures can be formed from agar (such as Gey's Agar), hydrogels (such as matrigel, agarose, and the like; Lee et al., (2004) Biomaterials 25: 2461-2466) or polymers that are cross-linked. These polymers can comprise natural polymers and their derivatives, synthetic polymers and their derivatives, or a combination thereof. Natural polymers can be anionic polymers, cationic polymers, amphipathic polymers, or neutral polymers. Non-limiting examples of anionic polymers can include hyaluronic acid, alginic acid (alginate), carageenan, chondroitin sulfate, dextran sulfate, and pectin. Some examples of cationic polymers, include but are not limited to, chitosan or polylysine. (Peppas et al., (2006) Adv Mater. 18: 1345-60; Hoffman, A. S., (2002) Adv Drug Deliv Rev. 43: 3-12; Hoffman, A. S., (2001) Ann NY Acad Sci 944: 62-73). Examples of amphipathic polymers can include, but are not limited to collagen, gelatin, fibrin, and carboxymethyl chitin. Non-limiting examples of neutral polymers can include dextran, agarose, or pullulan. (Peppas et al., (2006) Adv Mater. 18: 1345-60; Hoffman, A. S., (2002) Adv Drug Deliv Rev. 43: 3-12; Hoffman, A. S., (2001) Ann NY Acad Sci 944: 62-73).
- Cells suitable for culturing according to methods of the invention can harbor introduced expression vectors, such as plasmids. The expression vector constructs can be introduced via transformation, microinjection, transfection, lipofection, electroporation, or infection. The expression vectors can contain coding sequences, or portions thereof, encoding the proteins for expression and production. Expression vectors containing sequences encoding the produced proteins and polypeptides, as well as the appropriate transcriptional and translational control elements, can be generated using methods well known to and practiced by those skilled in the art. These methods include synthetic techniques, in vitro recombinant DNA techniques, and in vivo genetic recombination which are described in J. Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y. and in F. M. Ausubel et al., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y.
- A polypeptide molecule encoded by a gene, such as a p27 gene, or a variant thereof, can be obtained by purification from human cells expressing a protein or polypeptide encoded by a p27 gene via in vitro or in vivo expression of a nucleic acid sequence encoding a p27 protein or polypeptide: or by direct chemical synthesis.
- Host cells which contain a nucleic acid encoding a p27 protein or polypeptide, and which subsequently express a protein encoded by a p27 gene, can be identified by various procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a nucleic acid encoding a p27 protein or polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments of nucleic acids encoding a p27 protein or polypeptide. In one embodiment, a fragment of a nucleic acid of a p27 gene can encompass any portion of at least about 8 consecutive nucleotides of SEQ ID NO: 4. In another embodiment, the fragment can comprise at least about 10 consecutive nucleotides, at least about 15 consecutive nucleotides, at least about 20 consecutive nucleotides, or at least about 30 consecutive nucleotides of SEQ ID NO: 4. Fragments can include all possible nucleotide lengths between about 8 and about 100 nucleotides, for example, lengths between about 15 and about 100 nucleotides, or between about 20 and about 100 nucleotides. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a polypeptide encoded by a p27 gene to detect transformants which contain a nucleic acid encoding a p27 protein or polypeptide.
- Protocols for detecting and measuring the expression of a polypeptide encoded by a gene, such as a p27 gene, using either polyclonal or monoclonal antibodies specific for the polypeptide are well established. Non-limiting examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a polypeptide encoded by a gene, such as a p27 gene, can be used, or a competitive binding assay can be employed.
- Labeling and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Methods for producing labeled hybridization or PCR probes for detecting sequences related to nucleic acid sequences encoding a protein, such as, but not limited to, p27, include, but are not limited to, oligo labeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, nucleic acid sequences encoding a polypeptide encoded by a gene, such as a p27 gene, can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, and/or magnetic particles.
- Expression and Purification of Polypeptides
- Host cells transformed with a nucleic acid sequence encoding a polypeptide, such as, but not limited to, p27, can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. Expression vectors containing a nucleic acid sequence encoding a polypeptide, such as, but not limited to, p27, can be designed to contain signal sequences which direct secretion of soluble polypeptide molecules encoded by a gene, such as, but not limited to, p27, or a variant thereof, through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound a polypeptide molecule encoded by a p27 gene or a variant thereof.
- Other constructions can also be used to join a gene sequence encoding a polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Including cleavable linker sequences (i.e., those specific for Factor Xa or enterokinase (Invitrogen, San Diego, Calif.)) between the purification domain and a polypeptide encoded by a p27 gene, for example, also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide encoded by a p27 gene, for example, and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by immobilized metal ion affinity chromatography, while the enterokinase cleavage site provides a means for purifying the polypeptide encoded by a p27 gene.
- A p27 polypeptide can be purified from any human or non-human cell which expresses the polypeptide, including those which have been transfected with expression constructs that express a p27 protein. A purified p27 protein can be separated from other compounds which normally associate with a protein encoded by a p27 gene in the cell, such as certain proteins, carbohydrates, or lipids, using methods practiced in the art. Non-limiting methods include size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.
- Chemical Synthesis
- Nucleic acid sequences comprising a gene, such as, but not limited to, a p27 gene, that encodes a polypeptide can be synthesized, in whole or in part, using chemical methods known in the art. Alternatively, a polypeptide, such as, but not limited to, p27, can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of p27 polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule. In one embodiment, a fragment of a nucleic acid sequence that comprises a p27 gene can encompass any portion of at least about 8 consecutive nucleotides of SEQ ID NO: 4. In one embodiment, the fragment can comprise at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, or at least about 30 nucleotides of SEQ ID NO: 4. Fragments include all possible nucleotide lengths between about 8 and about 100 nucleotides, for example, lengths between about 15 and about 100 nucleotides, or between about 20 and about 100 nucleotides.
- Other nucleic acid sequences, such as, but not limited to, microRNA target sequences, can be synthesized, in whole or in part, using chemical methods known in the art. Automated synthesis can be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer). In one embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences can encompass any portion of at least about 4 consecutive nucleotides of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In one embodiment, the fragment can comprise at least about 6 nucleotides, at least about 8 nucleotides, at least about 10 nucleotides, or at least about 12 nucleotides, at least about 14 nucleotides, at least about 16 nucleotides of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. Fragments include all possible nucleotide lengths between about 4 and about 40 nucleotides, for example, lengths between about 10 and about 30 nucleotides, or between about 10 and about 20 nucleotides.
- In another embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences can encompass one or more nucleic acid sequences of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In one embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses one nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In another embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses two nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In one embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses three nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In another embodiment, a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses four nucleic acid sequence of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2. In other embodiments, a fragment of a nucleic acid sequence that comprises microRNA target sequences encompasses 5, 6, 7, 8, 9, 10, or more nucleic acid sequences of SEQ ID NO: 2, or any nucleic acid sequence complementary to SEQ ID NO. 2.
- A synthetic peptide can be substantially purified via high performance liquid chromatography (HPLC). The composition of a synthetic polypeptide of can be confirmed by amino acid analysis or sequencing. Additionally, any portion of an amino acid sequence comprising a protein encoded by a gene can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.
- Pharmaceutical Compositions
- In another aspect, the present invention provides for a composition comprising a nucleic acid vector, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest. In one embodiment, the composition is a pharmaceutical composition.
- In one embodiment, the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- In one embodiment, the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical. The nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In one embodiment, the second gene of interest is a human gene. In another embodiment, the second gene of interest is a non-human gene. In one embodiment, the second gene of interest is p53. In other embodiments, the second gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4. In one embodiment, the second gene of interest is an antithrombotic gene. In another embodiment, the second gene of interest is an anti-inflammatory gene. In another embodiment, the second gene of interest is ENTPD1, TFPI or PTGIS.
- In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the vector comprises one target sequence. In another embodiment, the vector comprises two target sequences. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the nucleic acid vector is a viral vector. In one embodiment, the viral vector is an adenoviral vector. In another embodiment, the viral vector is a lentiviral vector. In one embodiment, the vector is a retroviral vector. In another embodiment, is an oncoviral vector. Examples of adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12). In a further embodiment, the vector is an adeno-associated vector. Examples of adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2). Examples of lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2. Examples of retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV). Examples of oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- Methods of Treatment
- In yet another aspect, the invention provides a method of treating or preventing a cardiovascular disease in a subject in need thereof, the method comprising administering a nucleic acid vector to the subject, wherein the nucleic acid vector comprises a gene of interest and one or more target sequences for a microRNA within the 3′ UTR region of the gene of interest.
- In one embodiment, the gene of interest is a human gene. In another embodiment, the gene of interest is a non-human gene. In one embodiment, the gene of interest is a p27 gene. In another embodiment, the gene of interest is p53. In other embodiments, the gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1, BRAC2, or DPC4.
- In one embodiment, the microRNA is miR-126. In another embodiment, the micro-RNA is miR-143. In another embodiment, the micro-RNA is miR-145. In further embodiments, the microRNA is Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the one or more target sequences comprise SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise SEQ ID NO:2. In another embodiment, the one or more target sequences comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the one or more target sequences do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In one embodiment, the vector comprises four target sequences for a microRNA. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the target sequences for a microRNA are identical. In another embodiment, the target sequences for a microRNA are not identical. The nucleic acid vectors can comprise different combinations of target sequences for various microRNAs, including, but not limited to, miR-126, miR-143, miR-145, Let7-f, miR-27b, miR-130a, miR-221, miR-222, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a, miR-378, miR-210, miR-15, miR-16, miR-20b, miR-155, or miR-21.
- In one embodiment, the target sequences for a microRNA comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise SEQ ID NO:2. In another embodiment, the target sequences for a microRNA comprise a nucleic acid sequence complementary to SEQ ID NO:2. In another embodiment, the target sequences for a microRNA do not comprise a nucleic acid sequence complementary to SEQ ID NO:2.
- In another embodiment, the vector comprises a second gene of interest. In one embodiment, the second gene of interest is a human gene. In another embodiment, the second gene of interest is a non-human gene. In one embodiment, the second gene of interest is p53. In other embodiments, the second gene of interest is a tumor suppressor gene. A tumor suppressor gene can include, but is not limited to, APC, RB1, INK4, PTEN, MADR2, BRAC1. BRAC2, or DPC4. In one embodiment, the second gene of interest is an antithrombotic gene. In another embodiment, the second gene of interest is an anti-inflammatory gene. In another embodiment, the second gene of interest is ENTPD1, TFPI or PTGIS.
- In another embodiment, the vector comprises one or more target sequences for a microRNA within the 3′ UTR region of the second gene of interest. In one embodiment, the vector comprises one target sequence. In another embodiment, the vector comprises two target sequences. In another embodiment, the vector comprises three target sequences. In another embodiment, the vector comprises four target sequences. In another embodiment, the vector comprises five target sequences. In another embodiment, the vector comprises six target sequences. In another embodiment, the vector comprises seven target sequences. In another embodiment, the vector comprises eight target sequences. In other embodiments, the vector comprises nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more target sequences.
- In one embodiment, the nucleic acid vector is a viral vector. In one embodiment, the viral vector is an adenoviral vector. In another embodiment, the viral vector is a lentiviral vector. In one embodiment, the vector is a retroviral vector. In another embodiment, is an oncoviral vector. Examples of adenoviral vectors include vectors derived from adenoviruses such as, but not limited to, adenovirus type 2 (Ad2), adenovirus type 5 (Ad5), adenovirus type 7 (Ad7) and adenovirus type 12 (Ad12). In a further embodiment, the vector is an adeno-associated vector. Examples of adeno-associated vector includes vectors derived from adeno-associated viruses such as, but not limited to, adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 4 (AAV4), adeno-associated virus type 5 (AAV5), adeno-associated virus type 6 (AAV6), adeno-associated virus type 7 (AAV7), and adeno-associated virus type 2 (AAV2). Examples of lentiviral vectors include vectors derived from lentiviruses such as, but not limited to, HIV-1 and HIV-2. Examples of retroviral vectors include vectors derived from retroviruses such as, but not limited to, Moloney murine leukemia virus (MMLV). Examples of oncoviral vectors include vectors derived from oncoviruses such as, but not limited to, Murine Leukemia Virus (MLV), Spleen Necrosis Virus (SNV), Rous sarcoma virus (RSV) and Avian Leukosis Virus (ALV).
- In one embodiment, the nucleic acid vector is delivered into a cell of the subject. Delivery can be conducted by any method known to one of skill in the art, including, but not limited to, injection, transfection, lipofection, microinjection, calcium phosphate or calcium chloride precipitation, DEAE-dextrin-mediated transfection, or electroporation. Electroporation is carried out at approximate voltage and capacitance to result in entry of the DNA construct(s) into cells of interest. Other methods used to transfect cells can also include modified calcium phosphate precipitation, polybrene precipitation, liposome fusion, and receptor-mediated gene delivery.
- In another embodiment, the cell expresses the microRNA. In another embodiment, the cell does not express the microRNA.
- In one embodiment, the gene of interest is not expressed in the cell. In another embodiment, the gene of interest is expressed in the cell. In one embodiment, the second gene of interest is not expressed in the cell. In another embodiment, the second gene of interest is expressed in the cell.
- In one embodiment, the cell is an endothelial cell. In another embodiment, the cell is a vascular smooth muscle cell. In further embodiments, the cell may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell may be a stem cell or a differentiated cell. Cell types that are differentiated include, but are not limited to, adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of the endocrine and exocrine glands.
- In another embodiment, the cell is a cancer cell. The cancer can be, but is not limited to, breast cancer, lung cancer, kidney cancer, brain cancer, liver cancer, colorectal cancers, progressive lung adenocarcinoma, lymphomas, leukemias, adenocarcinomas and sarcomas.
- In one embodiment, the cardiovascular disease is coronary artery disease. In another embodiment, the cardiovascular disease is atherosclerotic coronary artery disease. In further embodiments, the cardiovascular disease includes, but is not limited to, coronary vasospasm, restenosis, myocardial ischemia, stent induced injury, stent thrombosis, cardiomyopathy, hypertensive heart disease, heart failure, cor pulmonale, cardiac dysrhythmias, inflammatory heart disease, valvular heart disease, peripheral arterial disease, cerebrovascular disease, congenital heart disease, atherosclerosis, arterial injury and rheumatic heart disease. The methods of the invention can also be used for other vascular conditions, such as vascular access failure, for example, in hemodialysis.
- Pharmaceutical Compositions and Administration for Therapy
- Nucleic acid vectors of the invention can be administered to the subject once (e.g., as a single injection or deposition). Alternatively, nucleic acid vectors of the invention can be administered once or twice daily to a subject in need thereof for a period of from about two to about twenty-eight days, or from about seven to about ten days. Nucleic acid vectors of the invention can also be administered once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof. Furthermore, nucleic acid vectors of the invention can be co-administrated with another therapeutic. Where a dosage regimen comprises multiple administrations, the effective amount of the nucleic acid vectors administered to the subject can comprise the total amount of the nucleic acid vectors administered over the entire dosage regimen.
- Nucleic acid vectors of the invention can be administered to a subject by any means suitable for delivering the nucleic acid vectors to cells of the subject. For example, nucleic acid vectors can be administered by methods suitable to transfect cells. Transfection methods for eukaryotic cells are well known in the art, and include direct injection of a nucleic acid into the nucleus or pronucleus of a cell; electroporation; liposome transfer or transfer mediated by lipophilic materials; receptor mediated nucleic acid delivery, bioballistic or particle acceleration; calcium phosphate precipitation, and transfection mediated by viral vectors.
- The nucleic acid vectors of the invention may be administered to a subject in an amount effective to treat or prevent a cardiovascular disease, such as, but not limited to, coronary artery disease. One of skill in the art can readily determine what will be an effective amount of the nucleic acid vectors of the invention to be administered to a subject, taking into account whether the nucleic acid vectors are being used prophylactically or therapeutically, and taking into account other factors such as the age, weight and sex of the subject, any other drugs that the subject may be taking, any allergies or contraindications that the subject may have, and the like. For example, an effective amount can be determined by the skilled artisan using known procedures, including analysis of titration curves established in vitro or in vivo. Also, one of skill in the art can determine the effective dose from performing pilot experiments in suitable animal model species and scaling the doses up or down depending on the subjects weight etc. Effective amounts can also be determined by performing clinical trials in individuals of the same species as the subject, for example starting at a low dose and gradually increasing the dose and monitoring the effects on a metabolic disorder, or coronary artery disease. Appropriate dosing regimens can also be determined by one of skill in the art without undue experimentation, in order to determine, for example, whether to administer the agent in one single dose or in multiple doses, and in the case of multiple doses, to determine an effective interval between doses.
- A therapeutically effective dose of a nucleic acid vector of the invention that treats or prevents a cardiovascular disease, such as, but not limited to, coronary artery disease, can depend upon a number of factors known to those of ordinary skill in the art. The dose(s) of the nucleic acid vectors can vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition comprising nucleic acid vectors is to be administered, if applicable, and the effect which the practitioner desires the nucleic acid vectors to have upon the target of interest. These amounts can be readily determined by a skilled artisan. Any of the therapeutic applications described herein can be applied to any subject in need of such therapy, including, for example, a mammal such as a dog, a cat, a cow, a horse, a rabbit, a monkey, a pig, a sheep, a goat, or a human.
- The compositions of this invention can be formulated and administered to reduce the symptoms associated with a cardiovascular disease, such as, but not limited to, coronary artery disease, by any means that produces contact of the active ingredient with the agent's site of action in the body of a subject, such as a human or animal (e.g., a dog, cat, or horse). They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
- Pharmaceutical compositions for use in accordance with the invention can be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. The therapeutic compositions of the invention can be formulated for a variety of routes of administration, including systemic or localized administration. Techniques and formulations generally can be found in Remmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, Pa. (20th Ed., 2000), the entire disclosure of which is herein incorporated by reference. For systemic administration, an injection is useful, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the therapeutic compositions of the invention can be formulated in liquid solutions, for example in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the therapeutic compositions can be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. These pharmaceutical formulations include formulations for human and veterinary use.
- According to the invention, a pharmaceutically acceptable carrier can comprise any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent that is compatible with the active ingredient can be used. Supplementary active compounds can also be incorporated into the compositions.
- The invention also provides for a kit that comprises a pharmaceutically acceptable carrier and one or more nucleic acid vector(s) of the invention packaged with instructions for use.
- A pharmaceutical composition containing nucleic acid vectors of the invention can be administered in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed herein. The compositions can be administered alone or in combination with at least one other agent, such as a stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
- A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it can be useful to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of injectable compositions can be brought about by incorporating an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the nucleic acid vectors of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the nucleic acid vectors into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated herein. In the case of sterile powders for the preparation of sterile injectable solutions, examples of useful preparation methods are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the nucleic acid vectors are formulated into ointments, salves, gels, or creams as generally known in the art. In some embodiments, the nucleic acid vectors can be applied via transdermal delivery systems, which slowly releases the nucleic acid vectors for percutaneous absorption. Permeation enhancers can be used to facilitate transdermal penetration of the active factors in the conditioned media. Transdermal patches are described in for example, U.S. Pat. No. 5,407,713; U.S. Pat. No. 5,352,456; U.S. Pat. No. 5,332,213; U.S. Pat. No. 5,336,168; U.S. Pat. No. 5,290,561; U.S. Pat. No. 5,254,346; U.S. Pat. No. 5,164,189; U.S. Pat. No. 5,163,899; U.S. Pat. No. 5,088,977; U.S. Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No. 4,921,475.
- Administration of the nucleic acid vectors is not restricted to a single route, but may encompass administration by multiple routes. For instance, exemplary administrations by multiple routes include, among others, a combination of intradermal and intramuscular administration, or intradermal and subcutaneous administration. Multiple administrations may be sequential or concurrent. Other modes of application by multiple routes will be apparent to the skilled artisan.
- The nucleic acid vectors of the invention may be formulated into compositions for administration to subjects for the treatment and/or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease. Such compositions may comprise the nucleic acid vectors of the invention in admixture with one or more pharmaceutically acceptable diluents and/or carriers and optionally one or more other pharmaceutically acceptable additives. The pharmaceutically-acceptable diluents and/or carriers and any other additives must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the subject to whom the composition will be administered. One of skill in the art can readily formulate the nucleic acid vectors of the invention into compositions suitable for administration to subjects, such as human subjects, for example using the teaching a standard text such as Remington's Pharmaceutical Sciences, 18th ed, (Mack Publishing Company: Easton, Pa., 1990), pp. 1635-36), and by taking into account the selected route of delivery.
- Examples of diluents and/or carriers and/or other additives that may be used include, but are not limited to, water, glycols, oils, alcohols, aqueous solvents, organic solvents, DMSO, saline solutions, physiological buffer solutions, peptide carriers, starches, sugars, preservatives, antioxidants, coloring agents, pH buffering agents, granulating agents, lubricants, binders, disintegrating agents, emulsifiers, binders, excipients, extenders, glidants, solubilizers, stabilizers, surface active agents, suspending agents, tonicity agents, viscosity-altering agents, carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, powders, saline, sodium alginate. The combination of diluents and/or carriers and/or other additives used can be varied taking into account the nature of the active agents used (for example the solubility and stability of the active agents), the route of delivery (e.g. oral, parenteral, etc.), whether the agents are to be delivered over an extended period (such as from a controlled-release capsule), whether the agents are to be co-administered with other agents, and various other factors. One of skill in the art will readily be able to formulate the nucleic acid vectors for the desired use without undue experimentation.
- The compositions of the invention may be administered to a subject by any suitable method that allows the agent to exert its effect on the subject in vivo. For example, the compositions may be administered to the subject by known procedures including, but not limited to, by oral administration, sublingual or buccal administration, parenteral administration, transdermal administration, via inhalation, via nasal delivery, vaginally, rectally, and intramuscularly. The compositions of the invention may be administered parenterally, or by epifascial, intracapsular, intracutaneous, subcutaneous, intradermal, intrathecal, intramuscular, intraperitoneal, intrasternal, intravascular, intravenous, parenchymatous, or sublingual delivery. Delivery may be by injection, infusion, catheter delivery, or some other means, such as by tablet or spray. In one embodiment, the nucleic acid vectors of the invention are administered to the subject by way of delivery directly to the heart tissue, such as by way of a catheter inserted into, or in the proximity of the subject's heart, or by using delivery vehicles capable of targeting the drug to the heart. For example, the nucleic acid vectors of the invention may be conjugated to or administered in conjunction with an agent that is targeted to the heart, such as an antibody or antibody fragment. In one embodiment, the nucleic acid vectors of the invention are administered to the subject by way of delivery directly to the tissue of interest, such as by way of a catheter inserted into, or in the proximity of the subject's tissue of interest, or by using delivery vehicles capable of targeting the nucleic acid vectors to the muscle, such as an antibody or antibody fragment.
- For oral administration, a formulation of the nucleic acid vectors of the invention may be presented as capsules, tablets, powders, granules, or as a suspension or solution. The formulation may contain conventional additives, such as lactose, mannitol, cornstarch or potato starch, binders, crystalline cellulose, cellulose derivatives, acacia, cornstarch, gelatins, disintegrators, potato starch, sodium carboxymethylcellulose, dibasic calcium phosphate, anhydrous or sodium starch glycolate, lubricants, and/or or magnesium stearate.
- For parenteral administration (i.e., administration by through a route other than the alimentary canal), the nucleic acid vectors of the invention may be combined with a sterile aqueous solution that is isotonic with the blood of the subject. Such a formulation may be prepared by dissolving the active ingredient in water containing physiologically-compatible substances, such as sodium chloride, glycine and the like, and having a buffered pH compatible with physiological conditions, so as to produce an aqueous solution, then rendering the solution sterile. The formulation may be presented in unit or multi-dose containers, such as sealed ampoules or vials. The formulation may be delivered by injection, infusion, or other means known in the art.
- For transdermal administration, the nucleic acid vectors of the invention may be combined with skin penetration enhancers, such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone and the like, which increase the permeability of the skin to the nucleic acid vectors of the invention and permit the nucleic acid vectors to penetrate through the skin and into the bloodstream. The nucleic acid vectors of the invention also may be further combined with a polymeric substance, such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like, to provide the composition in gel form, which are dissolved in a solvent, such as methylene chloride, evaporated to the desired viscosity and then applied to backing material to provide a patch.
- In some embodiments, the nucleic acid vectors of the invention are provided in unit dose form such as a tablet, capsule or single-dose injection or infusion vial.
- Combination Therapy
- According to the methods of the invention, a nucleic acid vector of the invention can be administered to a subject either as a single agent, or in combination with one or more other agents. In one embodiment, a nucleic acid vector of the invention is administered to a subject as a single agent. In one embodiment, a nucleic acid vector of the invention is administered to a subject alone. In one embodiment, a nucleic acid vector of the invention is administered to a subject in combination with one or more other agents.
- In certain embodiments, a nucleic acid vector of the invention may be used in combination with other agents that are used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject. In certain embodiments, a nucleic acid vector of the invention may be used in combination with other agents that are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject. In one embodiment, a nucleic acid vector of the invention may be delivered to a subject as part of the same pharmaceutical composition or formulation containing one or more additional active agents. In another embodiment, a nucleic acid vector of the invention may be delivered to a subject in a composition or formulation containing only that active agent, while one or more other agents are administered to the subject in one or more separate compositions or formulations. In one embodiment, the other agents are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject. In another embodiment, the other agents are used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject.
- A nucleic acid vector of the invention and the other agents that are used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease in a subject, may be administered to the subject at the same time, or at different times. A nucleic acid vector of the invention and the other agents that are not used for the treatment or prevention of a cardiovascular disease, such as, but not limited to, coronary artery disease, may be administered to the subject at the same time, or at different times. For example, a nucleic acid vector of the invention and the other agents may be administered within minutes, hours, days, weeks, or months of each other, for example as part of the overall treatment regimen of a subject. In some embodiments, a nucleic acid vector of the invention may be administered prior to the administration of other agents. In other embodiments, a nucleic acid vector of the invention may be administered subsequent to the administration of other agents.
- In some embodiments, the administration of a nucleic acid vector of the invention in combination with one or more other agents has an additive effect, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone. In other embodiments, the administration of a nucleic acid vector of the invention in combination with one or more other agents has a synergistic effect, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone. In some embodiments, the administration of a nucleic acid vector of the invention in combination with one or more other agents can help reduce side effects, in comparison with administration of the nucleic acid vector of the invention alone, or administration of the one or more other agents alone.
- In some embodiments, the nucleic acid vector of the invention is used as an adjuvant therapy. In other embodiments, the nucleic acid vector of the invention is used in combination with an adjuvant therapy.
- The invention may also be used in combination with known therapies for a cardiovascular disease. Examples include, but are not limited to, aspirin; statins, such as atorvastatin (Lipitor, Torvast), fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin (Livalo, Pitava), pravastatin (Pravachol, Selektine, Lipostat), rosuvastatin (Crestor), and simvastatin (Zocor, Lipex); nitroglycerin; angiotensin-converting enzyme (ACE) inhibitors, such as enalapril (Vasotec®), lisinopril (Zestril®, Prinvil®), ramipril (Altace®) and captopril (Capoten®); calcium channel blockers, such as verapamil (Calan®, Isoptin®); and beta-blockers, such as carvedilol (Cored®) and metoprolol (Lopressor®, Toprol XL®).
- The invention may also be used in combination with surgical or other interventional treatment regimens used for treatment of a cardiovascular disease, such as, but not limited to, use of a device, including, but not limited to, a stent, a rapamycin-coated stent, a drug-eluting stent, a bare-metal stent, a pacemaker, an implantable cardioverter-defibrillator (ICD) or a ventricular assist device (VAD).
- Subjects
- According to the methods of the invention, the subject or patient can be any animal that has or is diagnosed with a cardiovascular disease, such as, but not limited to, coronary artery disease. According to the methods of the invention, the subject or patient can be any animal that is predisposed to or is at risk of developing a cardiovascular disease, such as, but not limited to, coronary artery disease. In preferred embodiments, the subject is a human subject. In some embodiments, the subject is a rodent, such as a mouse. In some embodiments, the subject is a cow, pig, sheep, goat, cat, horse, dog, and/or any other species of animal used as livestock or kept as pets.
- In some embodiments, the subject is already suspected to have a cardiovascular disease, such as, but not limited to, coronary artery disease. In other embodiments, the subject is being treated for a cardiovascular disease, such as, but not limited to, coronary artery disease, before being treated according to the methods of the invention. In other embodiments, the subject is not being treated for a cardiovascular disease, such as, but not limited to, coronary artery disease, before being treated according to the methods of the invention.
- The following examples illustrate the present invention, and are set forth to aid in the understanding of the invention, and should not be construed to limit in any way the scope of the invention as defined in the statements of the invention which follow thereafter.
- The Examples described below are provided to illustrate aspects of the present invention and are not included for the purpose of limiting the invention.
- The numbers in parentheses below refer to the corresponding numbered reference(s) at the end of this section.
- Coronary artery disease (CAD) is a leading cause of death worldwide. Despite the benefits of drug-eluting stents (DES) concerns have been raised over their safety due to delayed endothelial cell (EC) coverage which promotes vascular restenosis and thrombosis, requiring prolonged dual anti-platelet therapy. Herein is shown a new therapeutic approach exploiting the EC specific microRNA-126 to prevent restenosis while preserving EC function.
- Percutaneous coronary intervention (PCI) is one of the most commonly performed interventions that have transformed the practice of revascularization for CAD (1). However, the major drawback of this procedure is the proliferation and subsequent accumulation of vascular smooth muscle cells (VSMC), leading to restenosis (2, 3). This process, also known as intimal hyperplasia, is triggered by the injury of the arterial wall and the concurrent endothelial denudation. The advent of DES, capable of delivering an inhibitor of cell proliferation in situ has decreased, but not eliminated, the occurrence of restenosis (2, 4). The drugs that elute from the stent not only inhibit VSMC, but also EC proliferation and migration (5, 6), increasing the risk of late thrombosis, a rare and potentially catastrophic event that is caused by incomplete re-endothelization (1, 7). The ideal therapy can provide VSMC-selective anti-proliferative activity without affecting EC.
- Recently, one of the crucial breakthroughs in the study of gene regulation has been the discovery of microRNAs (miRs), a class of endogenous small non-coding RNA (8, 9), miRs regulate the expression of much of the transcriptome via degradation of their target mRNA and/or inhibiting translation, miR-126 is expressed in a cell-specific manner (8, 10) that enabled to selectively inhibit VSMC proliferation while preserving the capability of EC to proliferate and migrate in order to re-endothelialize the vessel. Since the expression level of miR-126 is >600-fold higher in EC than in VSMC (
FIG. 2A ), this miR was selected to design a VSMC-specific therapy. - The cyclin-dependent kinase inhibitor p27KIP1 (p27) is known to be a potent inhibitor of cell proliferation (3). Different adenoviral (Ad) vectors were designed to overexpress p27 (
FIGS. 4A-C ): a CMV-GFP-p27 (Ad-p27) and a CMV-GFP-p27 containing 4 target sequences of miR-126 in its 3′UTR (Ad-p27-126TS) to selectively avoid overexpression of p27 in EC. A CMV-GFP virus (Ad-GFP) was used as control. EC and VSMC were infected with these Ad and the expressions of GFP and p27 were assessed by immunoblotting (FIGS. 2B,C). p27 was not overexpressed when Ad-GFP was used in both VSMC and EC, while p27 was highly overexpressed in both cell types when Ad-p27 was used. After Ad-p27-126TS infection, p27 was overexpressed in VSMC, which do not express mir-126. Since EC do express miR-126, which binds to the four target sequences in p27-3′UTR, p27 overexpression was abolished (FIGS. 2B,C). Next, the effect of the three Ad vectors on the proliferation (FIG. 2D ) and migration (FIGS. 2E-H ) of EC and VSMC was tested. Ad-p27 inhibited proliferation and migration >70% in both cell types (FIGS. 2D-H ). Importantly, VSMC infected with Ad-p27-126TS still showed >70% inhibition of proliferation and migration, while EC were not affected (FIGS. 2D-H ). In addition, EC network formation was examined. EC infected with Ad-p27, which overexpress p27, displayed a significant decrease in the network-like formation, whereas Ad-p27-126TS infected EC formed networks comparable to Ad-GFP infected cells (FIGS. 2I,J). - To test this approach in vivo, balloon injury of the rat carotid artery was used (11) and the injured vessel was infected with the three Ad. Two weeks after the injury, the efficiency of the infection (GFP immunostaining.
FIG. 5A ), the neointimal formation (FIG. 5B and FIGS. 4A,B) and the integrity of the endothelium (FIGS. 3A , C) were evaluated. Since pathological and clinical studies have reported incomplete neointimal coverage after PCI leading to thrombosis (12, 13), hypercoagulability was assessed by measuring plasma levels of D-dimer (14). The arteries infected with Ad-GFP demonstrated >2-fold increase in the neointima/media ratio after the balloon injury, and >80% decrease in re-endothelization (FIGS. 3A-C ), as well as higher levels of D-dimer (FIG. 3D ) compared to animals with uninjured arteries. Ad-p27 inhibited >85% of the neointimal formation and re-endothelization without affecting hypercoagulability (FIGS. 3A-D ). When Ad-p27-126TS was used, the inhibition of the neointimal formation was similar to Ad-p27, widespread re-endothelization was observed, and the D-dimer level was decreased similarly to the uninjured control (FIGS. 3A-D ). - To investigate whether the new endothelium was functional, a vascular reactivity assay was performed on carotid rings harvested from rats 2 weeks after vessel surgery (15). Carotid arteries infected with Ad-GFP displayed a blunted vasodilation response to acetylcholine, most likely due to restenosis (
FIG. 3E ). The Ad-p27-infected vessels also showed an impaired vasodilation response, comparable to denuded control vessels. Arteries infected with Ad-p27-126TS, in contrast, showed a normal vasodilation response, comparable to uninjured control vessels (FIG. 3E ). - Taken together, the data demonstrate for the first time that by exploiting the EC-specific miR-126, it is possible to specifically overexpress p27 in VSMC to inhibit proliferation and migration without affecting EC re-endothelialization. Normal endothelial function, as assessed by the reduction in D-dimer levels and acetylcholine-responsiveness, was also restored. This approach offers a basis for the development of new specific and selective therapeutic strategies to treat diverse pathological VSMC proliferative conditions, including restenosis, stent thrombosis, transplant vasculopathy, and vein graft failure. This new approach can be safer than the non-selective DES currently used in the clinical practice and can reduce the need for prolonged dual antiplatelet therapy following PCI. Further investigations can optimize the gene transfer to apply this approach in the clinical setting (8).
-
- 1. Garg, S. & Serruys, P. W. Journal of the American College of Cardiology 56, S1-42 (2010).
- 2. Jukema, J. W., Verschuren, J. J. W., Ahmed, T. A. N. & Quax, P. H. Nat. Rev. Cardiol. 9, 53-62 (2012).
- 3. Marx, S. O., Totary-Jain, H. & Marks, A. R. Circ Cardiovasc Interv 4, 104-111 (2011).
- 4. Cassese, S. & Kastrati, A. JAMA 308, 814-815 (2012).
- 5. Kotani, J., et al. Journal of the American College of Cardiology 47, 2108-2111 (2006).
- 6. Liu, H. T., et al. Tex
Heart Inst J 37, 194-201 (2010). - 7. Wenaweser. P., et al. Journal of the American College of Cardiology 52, 1134-1140 (2008).
- 8. van Rooij, E. & Olson, E. N. Nat Rev Drug Discov 11, 860-872 (2012).
- 9. Brown, B. D., Venneri, M. A., Zingale, A., Sergi Sergi, L. & Naldini, L. Nat Med 12, 585-591 (2006).
- 10. Wang, S., et al. Dev Cell 15, 261-271 (2008).
- 11. Iaccarino, G., Smithwick, L. A., Lefkowitz, R. J. & Koch, W. J. Proc Natl Acad Sci USA 96, 3945-3950 (1999).
- 12. Hayashi, S., et al. The American journal of pathology 175, 2226-2234 (2009).
- 13. Iakovou, I., et al. JAMA 293, 2126-2130 (2005).
- 14. Yamaguchi. K., et al. Int J Cardiol 153, 272-276 (2011).
- 15. Santulli, G., el al., J Am Heart Assoc 1, e001081 (2012).
- The numbers in parentheses below refer to the corresponding numbered reference(s) at the end of this section.
- Adenovirus Design.
- Recombinant adenoviruses containing human p27 (Ad-p27) and p27 that contains four tandem targeting sequences for hsa-miR-126-3p introduced in its 3′UTR region (Ad-p27-126TS) were constructed using AdEasy XL Adenoviral Vector System (Agilent Technologies, Santa Clara, Calif.), following the manufacturer's manual. Briefly, p27 was amplified with primers 5′-agtcggtaccaccATGTCAAACGTGCGAGTGTCTAACGG-3′ and 5′-gatctgtacaggatccTTACGTTTGACGTCTTCTGAGGCC-3′ (start and stop codons in bold and restriction sites in lowercase) and subcloned into a carrier vector. Complementary oligonucleotides containing four targeting sequences for miR-126 (in bold) (5′-aattcATCGCATTATTACTCACGGTACGAAATCCGCATTATTACTCACGGT ACGAAATCCGCATTATTACTCACGGTACGAAATCCGCATTATTACTCA CGGTACGAATg-3′ and 5′-aattcATTCGTACCGTGAGTAATAATGCGGATTTCGTACCGTGAGTAATA ATGCGGAITCGTACCGTGAGTAATAATGCGGATTTCGTACCGTGAGT AATAATGCGATg-3′) were annealed and subcloned in the 3′-UTR region of p27 with EcoRI. Next, p27 and p27-126TSx4 were amplified from the carrier vector with the following pairs of primers: 5′-agtcggtaccaccATGTCAAACGTGCGAGTGTCTAACGG-3′ as a sense primer for both constructs, and 5′-agtcctcgagTTACGTTTGACGTCTTCTGAGGCC-3′ and 5′-agtcctcgagaTTCGTACCGTGAGTAATAATGCGGATTTC-3′ as antisense primers for p27 and p27-126TSx4, respectively. The resulting PCR products were subcloned into pAdTrack-CMV shuttle vector (using Acc65 I and Xho I restriction sites in lowercase) under the control of a cytomegalovirus (CMV) promoter. All the constructs also contain a green fluorescence protein (GFP) under the control of a separate CMV promoter. All final virus constructs were purified by ultracentrifugation in CsCl gradient, dialyzed, confirmed by sequencing and titrated in HEK cells.
- Cell Culture.
- Human umbilical venous endothelial cells (HUVEC) were cultured in EGM2 Bullet Kit medium (Lonza, Basel, Switzerland) on dishes coated with type 1 rat tail collagen (VWR, Radnor, Pa.). Human umbilical vascular smooth muscle cells (VSMC) and SmGM-2 Bullet Kit medium were purchased from Lonza. The cells in all assays were below passage 6 and cultured at a density that allowed cell division throughout the course of the experiment.
- Quantitative Real Time-PCR.
- TaqMan® microRNA Assays (Life Technologies) were used to quantify mature miRNAs. cDNA was synthesized by priming with miRNA-specific looped primers, or U18 as endogenous control. Total RNA (100 ng) extracted with miRNeasy Mini Kit (Quiagen, Germantown, Md.) was used for each reverse transcription reaction according to the manufacturer's specifications and incubated for 30 min at 16° C., 30 min at 42° C., and 5 min at 85° C. and stored at 4° C. PCR was performed using 4.5 ng cDNA, 1× TaqMan® Universal PCR Master Mix (P/N: 4324018) and TaqMan® MicroRNA assay. All reactions, excluding no-template controls and non-reverse-transcribed controls were run in triplicate, incubated in 96-well plates at 95° C. for 20 seconds, followed by 40 cycles of 95° C. for 3 seconds and 60° C. for 30 seconds using the ABI 7500 Fast Real Time PCR Detection System. Real-time PCR data were analyzed using the comparative CT method, normalizing against the expression of U18.
- Proliferation, Migration, and Network Formation Assays.
- VSMC and EC were infected with 20 or 30 pfu/cell, respectively. Proliferation assay was carried out six days after infection by using the Cell-Proliferation-Reagent kit (Roche, Basel, Switzerland) according to the manufacturer's instruction. The absorbance was measured at 450 nm (with 690 nm reference wavelength) using Infinite® F500 microplate reader (Tecan, Männedorf, Switzerland). Cellular migration was assessed as previously described (1). The formation of network-like structures assay was performed and quantified as previously described and validated (1, 2). Several fields of view were captured per well and experiments were repeated three times by blinded observers.
- Immunoblotting.
- Immunoblot analysis was performed as previously described (3). Briefly, samples were resolved by SDS-PAGE and proteins transferred to poly-vinylidene difluoride and visualized by immunoblotting using infrared-labeled anti-rabbit (red) and anti mouse (green) secondary antibodies (1:10,000, LI-COR Biosciences. Lincoln, Nebr.). Band intensities were quantified with the Odyssey Infrared Imaging System (LI-COR Biosciences). Blots were probed with the following antibodies: rabbit anti-GAPDH (Cell signaling Technology®), rabbit anti-GFP (Life Technologies) and mouse anti-p27 (BD Transduction Laboratories™), San Jose, Calif.). Data are presented as arbitrary units after normalization for GAPDH as loading control.
- In Vivo Balloon Injury.
- The animals were housed in a 22° C. room with a 12-hour light/dark cycle. Balloon injury of the right carotid artery was performed in male Sprague Dawley rats (weighing 300±30 g, Harlan, South Easton, Mass.) using a HyperGlide™ ballon catheter (Micro Therapeutics, Inc. Irvine, Calif.), partially modifying a previously described procedure (4). Briefly, the animals were anesthetized by isoflurane (4%) inhalation and maintained by mask ventilation (isoflurane 2%), and the right common, external and internal carotid arteries were exposed and isolated. Through the external carotid, the balloon catheter was introduced in the common carotid and inflated 7 times. After injury, the common carotid artery was flushed twice with PBS, and a solution of PBS and adenovirus [5×109 plaque-forming unit (pfu)/100 μl] was injected and allowed to incubate in the common carotid in the absence of flow for 20 min. During this procedure the tension of common carotid artery was maintained by placing microvascular clips (Harvard Apparatus, Holliston, Mass.) on the internal and the common carotids (5). The adenovirus then was removed, the external carotid was tied and the blood flow was restored through the common and the internal carotid arteries. Following wound closure, the rats were given ad libitum access to food and water. All experiments were performed by blinded investigators.
- D-Dimer Measurement.
- Hypercoagulability was assessed measuring plasma levels of D-dimer (6) using a rat immunoassay (USCN Life Science Inc. Houston, Tex.) in accordance to the manufacturer's instructions.
- Morphological Analysis.
- Two weeks after surgery, the rats were euthanized and the carotid arteries were fixed by perfusion at 100 mmHg with 100 ml of PBS, followed by 80 ml of PBS containing 4% paraformaldehyde via a cannula placed in the left ventricle. Both right and left common carotid arteries were then excised, cut in two portions and embedded in optimal cutting temperature (OCT) medium (Sakura Finetek, Tokyo, Japan) for cryosectioning. Subsequently, 10 μm sections were cut every 20 μm and submitted in toto for histological evaluation. Sections were processed for staining with anti-α-smooth muscle actin (α-SMA, Sigma-Aldrich, 1:1000 for 3 h at room temperature), anti VE cadherin (Abeam, Cambridge, Mass., 1:100 overnight at 4° C.) specific for EC (7), anti GFP (Life Technologies, 1:1000 overnight at 4° C.) antibodies. Fluorescent-labeled secondary antibodies (1:1000) were incubated at room temperature for 1 hour. Samples were then washed with PBS and mounted with SlowFade® Gold antifade reagent with DAPI (Life Technologies). Images were taken by using a Nikon A1 scanning confocal microscope (Nikon Instruments, Melville, N.Y.) and acquired with NIS-Elements advanced research software. Images were optimized for contrast, without any further manipulation. Neointima/media ratios were calculated using a computerized image analysis system (Image J), as previously described (4).
- Vascular Reactivity.
- After isolation from the rats, common carotid arteries were suspended in isolated tissue baths filled with 25 mL Krebs-Henseleit solution (in mMol/L: NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25, and glucose 5.6) continuously bubbled with a mixture of 5% CO2 and 95% O2 (pH 7.38 to 7.42) at 37° C. as previously described (8). Endothelium-dependent vasorelaxation was assessed in vessels pre-constricted with phenylephrine (10−5 M) in response to acetylcholine from 10−9 to 10−6 M, freshly prepared on the day of experiment (5, 9). Concentrations are reported as the final molar value in the organ bath. Endothelium-independent vasodilatation was tested after mechanical endothelium removal of the endothelial layer. -
- 1. Ciccarelli, M., et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 153, 936-946 (2008).
- 2. Santulli, G., et al. Evaluation of the anti-angiogenic properties of the new selective alpha Vbeta3 integrin antagonist RGDechiHCit. J Transl Med 9, 7 (2011).
- 3. Totary-Jain, H., et al. Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res 72, 1836-1843 (2012).
- 4. Iaccarino, G., Smithwick, L. A., Lefkowitz, R. J. & Koch, W. J. Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci USA 96, 3945-3950 (1999).
- 5. Iaccarino, G., et al. AKT participates in endothelial dysfunction in hypertension. Circulation 109, 2587-2593 (2004).
- 6. Yamaguchi, K., et al. Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina. Int J Cardiol 153, 272-276 (2011).
- 7. Vestweber, D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vase Biol 28, 223-232 (2008).
- 8. Santulli. G., et al. In vivo properties of the proangiogenic peptide QK. J Transl Med 7, 41 (2009).
- 9. Santulli, G., et al. CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc 1, e001081 (2012).
- Coronary artery disease is currently a leading cause of death worldwide.
- Despite all the benefits of drug-eluting stents (DES), concerns have been raised over their long-term safety, with particular reference to stent thrombosis due to delayed endothelial cell (EC) coverage. Described herein is a method that exploits the endogenous miRNAs to specifically inhibit vascular smooth muscle cell (VSMC) proliferation, the major cause of restenosis, without affecting reendothelialization.
- By inserting four target sequences of the EC specific mir-126 into the 3′UTR of p27 expressing adenoviruses (p27-126TS), VSMC proliferation and migration was specifically inhibited, while EC were able to proliferate, migrate and form capillary-like networks. Balloon injured rat carotid artery infected with p27-126TS viruses exhibited complete inhibition of restenosis with complete re-endothelialization after two weeks (
FIG. 3B ). Moreover, hypercoagulability assessed by measuring plasma levels of D-dimer in the serum of rats treated with the p27-126TS was similar to the non-injured control (FIG. 3D ). Finally, the vasodilatative response to acetylcholine of balloon injured carotid arteries treated with p27-126TS adenovirus were comparable to those of the control-noninjured vessel (FIG. 3E ). The data above can lead to a safer therapy than the non-selective DES and can diminish the need for prolonged dual antiplatelet therapy following percutaneous coronary intervention. - Antithrombotic and/or antiinflammatory genes will be incorporated into the adenovirus expression vectors described in the examples above, or into any other DNA delivery system, as described in the Detailed Description. Such genes will be incorporated into the adenovirus vectors under the control of a second CMV promoter.
- Example antithrombotic and/or antiinflammatory genes include the following:
-
- Ectonucleoside triphosphate diphosphohydrolase, ENTPD1. The nucleic acid sequence of the gene encoding ENTPD1, including, but not limited to, the nucleic acid sequence of the open reading frame of the gene, is known in the art. The nucleic acid sequence of the gene encoding human ENTPD1, including, but not limited to, the nucleic acid sequence of the open reading frame of the human gene, is known in the art. The amino acid sequences of the ENTPD1 polypeptide and protein, including, but not limited to, the amino acid sequences of the human ENTPD1 polypeptide and proteins, are known in the art. The GenBank accession number of a polypeptide sequence of human ENTPD1 is AAH47664.
- Prostacyclin synthase, PTGIS. The nucleic acid sequence of the gene encoding PTGIS, including, but not limited to, the nucleic acid sequence of the open reading frame of the gene, is known in the art. The nucleic acid sequence of the gene encoding human PTGIS, including, but not limited to, the nucleic acid sequence of the open reading frame of the human gene, is known in the art. The amino acid sequences of the PTGIS polypeptide and protein, including, but not limited to, the amino acid sequences of the human PTGIS polypeptide and proteins, are known in the art. The GenBank accession number of a polypeptide sequence of human PTGIS is BAA11910.
- Tissue factor pathway inhibitor, TFPI. The nucleic acid sequence of the gene encoding TFPI, including, but not limited to, the nucleic acid sequence of the open reading frame of the gene, is known in the art. The nucleic acid sequence of the gene encoding human TFPI, including, but not limited to, the nucleic acid sequence of the open reading frame of the human gene, is known in the art. The amino acid sequences of the TFPI polypeptide and protein, including, but not limited to, the amino acid sequences of the human TFPI polypeptide and proteins, are known in the art. The GenBank accession number of the nucleic acid sequence of human TFPI is AF021834.
Claims (65)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/390,988 US20150190532A1 (en) | 2012-04-04 | 2013-04-04 | Smooth muscle specific inhibition for anti-restenotic therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261620404P | 2012-04-04 | 2012-04-04 | |
US201261727003P | 2012-11-15 | 2012-11-15 | |
US14/390,988 US20150190532A1 (en) | 2012-04-04 | 2013-04-04 | Smooth muscle specific inhibition for anti-restenotic therapy |
PCT/US2013/035327 WO2013152230A1 (en) | 2012-04-04 | 2013-04-04 | Smooth muscle specific inhibition for anti-restenotic therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/035327 A-371-Of-International WO2013152230A1 (en) | 2012-04-04 | 2013-04-04 | Smooth muscle specific inhibition for anti-restenotic therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/806,007 Division US10925976B2 (en) | 2012-04-04 | 2017-11-07 | Smooth muscle specific inhibition for anti-restenotic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150190532A1 true US20150190532A1 (en) | 2015-07-09 |
Family
ID=49301062
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/390,988 Abandoned US20150190532A1 (en) | 2012-04-04 | 2013-04-04 | Smooth muscle specific inhibition for anti-restenotic therapy |
US15/806,007 Active US10925976B2 (en) | 2012-04-04 | 2017-11-07 | Smooth muscle specific inhibition for anti-restenotic therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/806,007 Active US10925976B2 (en) | 2012-04-04 | 2017-11-07 | Smooth muscle specific inhibition for anti-restenotic therapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US20150190532A1 (en) |
WO (1) | WO2013152230A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
WO2023164708A1 (en) * | 2022-02-25 | 2023-08-31 | University Of South Florida | Design and development of a novel messenger rna therapeutic to treat atherosclerosis |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150190532A1 (en) | 2012-04-04 | 2015-07-09 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
CN105950660B (en) * | 2016-06-27 | 2019-11-01 | 姚陈 | Adenovirus vector and its application of one species specificity inhibition smooth muscle cell proliferation and migration |
ES2938458T3 (en) * | 2017-07-31 | 2023-04-11 | Canto Zago Alexandre Do | Device and method for promoting rapid coverage of structural mesh and vascular endothelial coverage |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090137421A1 (en) * | 2007-10-25 | 2009-05-28 | Board Of Trustees Of Southern Illinois University | GENETIC SELECTION SYSTEM FOR IDENTIFICATION OF MicroRNA TARGET GENES |
US20110172293A1 (en) * | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
US20120128643A1 (en) * | 2009-04-30 | 2012-05-24 | Fondazione Telethon | Gene vector |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
CA2108144A1 (en) | 1991-03-06 | 1992-09-07 | Jack A. Roth | Methods and compositions for the selective inhibition of gene expression |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US7419661B2 (en) | 1997-04-30 | 2008-09-02 | The Centre Of Excellence For Life Sciences Limited | Dermal sheath tissue in wound healing |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
GB9925964D0 (en) | 1999-11-03 | 1999-12-29 | Jahoda Colin A B | Hair transplantation |
EP2428569B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
KR20130114758A (en) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Gene vector comprising mi-rna |
JP2009517343A (en) | 2005-11-14 | 2009-04-30 | エンタープライズ パートナーズ ベンチャー キャピタル | Stem cell factor therapy for tissue damage |
EP1974044B1 (en) | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
WO2007100870A2 (en) | 2006-02-28 | 2007-09-07 | The Trustees Of Columbia University In The City Of New York | Methods for compact aggregation of dermal cells |
WO2008073921A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-126 regulated genes and pathways as targets for therapeutic intervention |
WO2009149182A1 (en) * | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
CA2733556A1 (en) | 2008-08-11 | 2010-02-18 | The Board Of Regents Of The University Of Texas System | A micro-rna that promotes vascular integrity and uses thereof |
EP2327781A1 (en) | 2009-11-27 | 2011-06-01 | RWTH Aachen | Micro-RNA and tissue repair |
JP5985474B2 (en) | 2010-08-04 | 2016-09-06 | メリル ライフ サイエンシズ ピーブィティ.エルティディ | Process for the preparation of novel 42-O- (heteroalkoxyalkyl) rapamycin compounds with antiproliferative properties |
US20150190532A1 (en) | 2012-04-04 | 2015-07-09 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
-
2013
- 2013-04-04 US US14/390,988 patent/US20150190532A1/en not_active Abandoned
- 2013-04-04 WO PCT/US2013/035327 patent/WO2013152230A1/en active Application Filing
-
2017
- 2017-11-07 US US15/806,007 patent/US10925976B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090137421A1 (en) * | 2007-10-25 | 2009-05-28 | Board Of Trustees Of Southern Illinois University | GENETIC SELECTION SYSTEM FOR IDENTIFICATION OF MicroRNA TARGET GENES |
US20110172293A1 (en) * | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
US20120128643A1 (en) * | 2009-04-30 | 2012-05-24 | Fondazione Telethon | Gene vector |
Non-Patent Citations (3)
Title |
---|
Brown et al (Nature Medicine. 23 April. 2006; 12(5): 585-591) * |
Brown et al. (Nature Medicine. 23 April 2006; 12(5): 585-591) * |
Zhu et al. (Journal of Biological Chemistry. May 11, 2007; 282(19: 14328-14336). * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
US10709759B1 (en) | 2015-10-23 | 2020-07-14 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
US11857598B2 (en) | 2015-10-23 | 2024-01-02 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
WO2023164708A1 (en) * | 2022-02-25 | 2023-08-31 | University Of South Florida | Design and development of a novel messenger rna therapeutic to treat atherosclerosis |
Also Published As
Publication number | Publication date |
---|---|
US20180110879A1 (en) | 2018-04-26 |
WO2013152230A1 (en) | 2013-10-10 |
US10925976B2 (en) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10925976B2 (en) | Smooth muscle specific inhibition for anti-restenotic therapy | |
Chen et al. | MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction | |
Wang et al. | CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction | |
Meloni et al. | Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction | |
Suh et al. | Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation | |
Zhou et al. | miR-30a negatively regulates TGF-β1–induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1 | |
DK2217704T3 (en) | Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis | |
He et al. | MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS | |
EP2454370B1 (en) | Microrna-24 | |
ES2651515T3 (en) | The miRNA-212/132 family as a therapeutic target | |
WO2012149646A1 (en) | Mirna inhibitors and their uses | |
JP2021519587A (en) | MicroRNA expression constructs and their use | |
Chen et al. | Lnc-Ang362 is a pro-fibrotic long non-coding RNA promoting cardiac fibrosis after myocardial infarction by suppressing Smad7 | |
Li et al. | MicroRNA‐129‐1‐3p regulates cyclic stretch–induced endothelial progenitor cell differentiation by targeting Runx2 | |
US11702657B2 (en) | TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma | |
ES2434172T3 (en) | MRP4 inhibitors for the treatment of vascular disorders | |
Zhang et al. | LncRNA AZIN1-AS1 ameliorates myocardial ischemia–reperfusion injury by targeting miR-6838-5p/WNT3A axis to activate Wnt-β/catenin signaling pathway | |
AU2011256098A1 (en) | Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas | |
US20180008641A1 (en) | Use of MicroRNA 375 in Augmenting Stem Cell Based and Endogenous Ischemic Tissue Repair | |
US20220186228A1 (en) | Synthetic microrna mimics | |
Chen et al. | YY1/miR-140-5p/Jagged1/Notch axis mediates cartilage progenitor/stem cells fate reprogramming in knee osteoarthritis | |
Yue et al. | Mesenchymal stem cells-derived exosomal microRNA-182-5p downregulates gasdermin D and ameliorates myocardial ischemia/reperfusion injury | |
US20230058864A1 (en) | Compositions and methods for treating pathologic calcification | |
Remes | Therapeutic transcription factor decoy oligodeoxynucleotides for Marfan syndrome and heart failure | |
Ying et al. | Resident vascular Sca1+ progenitors differentiate into endothelial cells in vascular remodeling via miR-145-5p/ERG signaling pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOTARY-JAIN, HANA;MARKS, ANDREW ROBERT;MARX, STEVEN O;SIGNING DATES FROM 20150424 TO 20150522;REEL/FRAME:035701/0093 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:COLUMBIA UNIV NEW YORK MORNINGSIDE;REEL/FRAME:042457/0300 Effective date: 20170508 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |